Document:

Exhibit 10.8

 

EXECUTION VERSION

 

STOCKHOLDER AND REGISTRATION RIGHTS AGREEMENT

 

This STOCKHOLDER AND REGISTRATION RIGHTS
AGREEMENT, dated as of November 2 , 2021 (this “Agreement”), is by and between International Business Machines
Corporation, a New York corporation (“IBM”), and Kyndryl Holdings, Inc., a Delaware corporation
(“Kyndryl”).

 

WHEREAS, IBM currently owns all of the issued
and outstanding shares of common stock, par value $0.01 per share, of Kyndryl (“Kyndryl Common Stock”);

 

WHEREAS, pursuant to the Separation and
Distribution Agreement, dated as of  November 2 , 2021, by and between IBM and Kyndryl, IBM will distribute   80.1%
of the issued and outstanding shares of Kyndryl Common Stock to holders of shares of IBM common stock, on a pro rata basis (the
 “Distribution”);

 

WHEREAS, in connection with the Distribution, Kyndryl
will register shares of Kyndryl Common Stock under the Exchange Act (as defined below) on a registration statement on Form 10;

 

WHEREAS, following the Distribution, IBM may
effect distributions of any shares of Kyndryl Common Stock that are not distributed in the Distribution (such shares not distributed in
the Distribution, the “Retained Shares”) to IBM stockholders as dividends or in exchange for outstanding shares of
IBM common stock or through one or more subsequent exchanges of Kyndryl Common Stock for IBM debt held by IBM creditors, including pursuant
to one or more transactions Registered under the Securities Act (as such terms are defined below);

 

WHEREAS, Kyndryl desires to grant to IBM the Registration
Rights (as defined below) for the Registrable Securities (as defined below), subject to the terms and conditions of this Agreement; and

 

WHEREAS, IBM desires to grant to Kyndryl a
proxy to vote the Retained Shares in proportion to the votes cast by Kyndryl’s other stockholders, subject to the terms and conditions
of this Agreement.

 

NOW, THEREFORE, in consideration of the foregoing
and the mutual promises, covenants and agreements of the parties hereto, and for other good and valuable consideration the receipt and
sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

ARTICLE I

 

DEFINITIONS

 

1.1            Defined
Terms. As used in this Agreement, the following terms shall have the following meanings:

 

“AAA” has the meaning set forth
in Section 4.4(c).

 

    	 	 	 

     

    

 

“Action” means any demand,
action, suit, countersuit, arbitration, inquiry, proceeding or investigation by or before any federal, state, local, foreign or international
Governmental Authority or any arbitration or mediation tribunal.

 

“Affiliate” means, when used
with respect to a specified Person, another Person that controls, is controlled by, or is under common control with the Person specified;
provided, however, that, for purposes of this Agreement, Kyndryl and its Subsidiaries shall not be considered to be “Affiliates”
of IBM and its Subsidiaries (other than Kyndryl and its Subsidiaries), and IBM and its Subsidiaries (other than Kyndryl and its Subsidiaries)
shall not be considered to be “Affiliates” of Kyndryl or its Subsidiaries. As used herein, “control” means
the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such person, whether
through the ownership of voting securities or other interests, by contract or otherwise.

 

“Agreement” has the meaning
set forth in the preamble to this Agreement.

 

“Ancillary Filings” has the
meaning set forth in Section 2.4(a)(i).

 

“Arbitral Tribunal” has the
meaning set forth in Section 4.4(c)(i).

 

“Block Trade” means an Underwritten
Offering not involving any “road show” which is commonly known as a “block trade.”

 

“Business Day” means any day
that is not a Saturday, Sunday or other day on which banking institutions doing business in New York, New York are authorized or obligated
by law or required by executive order to be closed.

 

“Chosen Court Claim” has the
meaning set forth in Section 4.6.

 

“Chosen Courts” has the meaning
set forth in Section 4.6.

 

“Convertible or Exchange Registration”
has the meaning set forth in Section 2.7.

 

“Debt” means any indebtedness
of any member of the IBM Group, including debt securities, notes, credit facilities, credit agreements and other debt instruments, including,
in each case, any amounts due thereunder.

 

“Demand Registration” has the
meaning set forth in Section 2.1(a).

 

“Decision on Interim Relief”
has the meaning set forth in Section 4.4(c)(iv).

 

“Dispute” or “Disputes”
has the meaning set forth in Section 4.4(b).

 

“Dispute Notice” has the meaning
set forth in Section 4.4(b).

 

“Distribution” has the meaning
set forth in the recitals to this Agreement.

 

    	 	2	 

     

    

 

“Exchange Act” means the Securities
Exchange Act of 1934, as amended, and any successor thereto, and any rules and regulations promulgated thereunder, all as the same
shall be in effect from time to time.

 

“Exchange Offer” means an exchange
offer of Registrable Securities for outstanding securities of a Holder.

 

“Exchanges” means one or more
Public Exchanges or Private Exchanges.

 

“Governmental Authority” means
any nation or government, any state, municipality or other political subdivision thereof, and any entity, body, agency, commission, department,
board, bureau, court, tribunal or other instrumentality, whether federal, state, local, domestic, foreign or multinational, exercising
executive, legislative, judicial, regulatory, administrative or other similar functions of, or pertaining to, government and any executive
official thereof.

 

“Holder” means IBM or any of
its Subsidiaries, so long as such Person holds any Registrable Securities, and any Person owning Registrable Securities who is a Permitted
Transferee of rights under Section 4.3.

 

“IBM” has the meaning set forth
in the preamble to this Agreement and shall include its successors, by merger, acquisition, reorganization or otherwise.

 

“IBM Group” means IBM and each
Person that is a direct or indirect Subsidiary of IBM as of immediately following the Distribution, and each Person that becomes a Subsidiary
of IBM after the Distribution (in each case other than any member of the Kyndryl Group).

 

“Initiating Holder” has the
meaning set forth in Section 2.1(a).

 

“Interim Relief” has the meaning
set forth in Section 4.4(c)(iv).

 

“Kyndryl” has the meaning set
forth in the preamble to this Agreement and shall include its successors, by merger, acquisition, reorganization or otherwise.

 

“Kyndryl Common Stock” has the
meaning set forth in the recitals to this Agreement.

 

“Kyndryl Group” means Kyndryl
and each Person that is a direct or indirect Subsidiary of Kyndryl as of immediately following the Distribution, and each Person that
becomes a Subsidiary of Kyndryl after the Distribution (in each case other than any member of the IBM Group).

 

“Kyndryl Notice” has the meaning
set forth in Section 2.1(a).

 

“Kyndryl Public Sale” has the
meaning set forth in Section 2.2(a).

 

“Kyndryl Takedown Notice” has
the meaning set forth in Section 2.1(f).

 

“Loss” or “Losses”
has the meaning set forth in Section 2.9(a).

 

“Negotiation Period” has the
meaning set forth in Section 4.4(b).

 

    	 	3	 

     

    

 

“Participating Banks” means
such investment banks or other Persons that are not part of the IBM Group that engage, directly or indirectly, in any Exchange with one
or more members of the IBM Group.

 

“Permitted Transferee” means
any Transferee and any Subsequent Transferee.

 

“Person” means any individual,
firm, limited liability company or partnership, joint venture, corporation, joint stock company, trust or unincorporated organization,
incorporated or unincorporated association, government (or any department, agency or political subdivision thereof) or other entity of
any kind, and shall include any successor (by merger or otherwise) of such entity.

 

“Piggyback Registration” has
the meaning set forth in Section 2.2(a).

 

“Private Exchange” means a private
exchange pursuant to which one or more members of the IBM Group shall Sell some or all of their Registrable Securities to one or more
Participating Banks in exchange, directly or indirectly, for any equity interest of IBM or the satisfaction of Debt, in a transaction
or series of transactions not required to be registered under the Securities Act.

 

“Prospectus” means the prospectus
included in any Registration Statement, all amendments and supplements to such prospectus, including post-effective amendments, and all
other material incorporated by reference in such prospectus.

 

“Public Exchange” means a public
exchange pursuant to which one or more members of the IBM Group shall Sell some or all of their Registrable Securities to one or more
Participating Banks in exchange, directly or indirectly, for any equity interest of IBM or the satisfaction of Debt, in a transaction
or series of transactions registered under the Securities Act.

 

“Registrable Securities” means
any Retained Shares and any securities issued or issuable directly or indirectly with respect to, in exchange for, upon the conversion
of or in replacement of the Retained Shares, whether by way of a dividend or distribution or stock split or in connection with a combination
of shares, recapitalization, merger, consolidation, exchange or other reorganization. The term “Registrable Securities”
excludes any security (i) the offering and Sale of which has been effectively Registered under the Securities Act and which has been
Sold in accordance with a Registration Statement, (ii) that has been Sold pursuant to Rule 144 (or any successor provision)
under the Securities Act, (iii) that (A) may be Sold pursuant to Rule 144 (or any successor provision) under the Securities
Act without being subject to the volume limitations in subsection (e) of such rule and (B) is held by a Holder of less
than 1% of the then-issued and outstanding shares of Kyndryl Common Stock (determined, in the case of IBM or any of its direct or indirect
Subsidiaries, as applicable, as the aggregate number of Registrable Securities held by the IBM Group) or (iv) that has been sold
by a Holder in a transaction in which such Holder’s rights under this Agreement are not, or cannot be, assigned.

 

“Registration” means a registration
with the SEC of the offer and Sale to the public of any Kyndryl Common Stock under a Registration Statement. The terms “Register,”
 “Registered” and “Registering” shall have a correlative meaning.

 

    	 	4	 

     

    

 

“Registration Expenses” means
all expenses incident to Kyndryl’s performance of or compliance with this Agreement, including all (i) registration, qualification
and filing fees; (ii) expenses incurred in connection with the preparation, printing and filing under the Securities Act of the Registration
Statement, any Prospectus and any issuer free writing prospectus and the distribution thereof; (iii) the fees and expenses of Kyndryl’s
counsel and independent accountants (including the expenses of any comfort letters or costs associated with the delivery by Kyndryl Group
members’ independent certified public accountants of comfort letters customarily requested by underwriters); (iv) the fees
and expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the Shares
under the state or foreign securities or blue sky laws and the preparation, printing and distribution of a Blue Sky Memorandum (including
the related reasonable fees and expenses of counsel); (v) the costs and charges of any transfer agent and any registrar; (vi) all
expenses and application fees incurred in connection with any filing with, and clearance of an offering by, Financial Industry Regulatory
Authority, Inc.; (vii) printing expenses, messenger, telephone and delivery expenses; (viii) internal expenses of Kyndryl
(including all salaries and expenses of employees of Kyndryl performing legal or accounting duties); (ix) fees and expenses of listing
any Registrable Securities on any securities exchange on which shares of Kyndryl Common Stock are then listed; and (x) the reasonable
fees and expenses of one legal counsel chosen by IBM or the Holders of a majority of the Registrable Securities included in a Demand Registration,
Piggyback Registration or Shelf Registration (including Block Trades), as applicable; but excluding any underwriting discounts or commissions
attributable to the Sale of any Registrable Securities, any fees and expenses of any other counsel, accountants or other persons retained
or employed by any Holder, any fees and expenses of any counsel to the underwriters or dealer managers and any stock transfer taxes.

 

“Registration Period” has the
meaning set forth in Section 2.1(c).

 

“Registration Rights” means
the rights of the Holders to cause Kyndryl to Register Registrable Securities pursuant to this Agreement.

 

“Registration Statement” means
any registration statement of Kyndryl filed with, or to be filed with, the SEC under the rules and regulations promulgated under
the Securities Act, including the related Prospectus, amendments and supplements to such registration statement, including post-effective
amendments, and all exhibits and all material incorporated by reference in such registration statement.

 

“Retained Shares” has the meaning
set forth in the recitals to this Agreement.

 

“Rules” has the meaning set
forth in Section 4.4(c).

 

“Sale” means the direct or indirect
transfer, sale, assignment or other disposition of a security. The terms “Sell” and “Sold” have correlative meanings.

 

“SEC” means the Securities and
Exchange Commission.

 

“Securities Act” means the U.S.
Securities Act of 1933, as amended, and any successor thereto, and any rules and regulations promulgated thereunder, all as the same
shall be in effect from time to time.

 

    	 	5	 

     

    

 

“Shares” means all shares of
Kyndryl Common Stock that are beneficially owned by IBM or any Permitted Transferee from time to time, whether or not held immediately
following the Distribution.

 

“Shelf Registration” means a
Registration Statement of Kyndryl for an offering to be made on a delayed or continuous basis of Kyndryl Common Stock pursuant to Rule 415
under the Securities Act (or similar provisions then in effect).

 

“Subsequent Transferee” has
the meaning set forth in Section 4.3(b).

 

“Subsidiary” means, with respect
to any Person, any corporation, limited liability company, joint venture or partnership of which such Person (i) beneficially owns,
either directly or indirectly, more than fifty percent (50%) of (A) the total combined voting power of all classes of voting securities
of such Person, (B) the total combined equity interests or (C) the capital or profit interests, in the case of a partnership,
or (ii) otherwise has the power to vote, either directly or indirectly, sufficient securities to elect a majority of the board of
directors or similar governing body.

 

“Takedown Notice” has the meaning
set forth in Section 2.1(f).

 

“Takedown Prospectus Supplement”
has the meaning set forth in Section 2.1(f).

 

“Transferee” has the meaning
set forth in Section 4.3(b).

 

“Underwritten Offering” means
a Registration in which securities of Kyndryl are Sold to an underwriter or underwriters on a firm commitment basis for reoffering to
the public.

 

1.2            General
Interpretive Principles. Whenever used in this Agreement, except as otherwise expressly provided or unless the context otherwise requires,
any noun or pronoun shall be deemed to include the plural as well as the singular and to cover all genders. Whenever the words “include,”
 “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without
limitation.” Unless otherwise specified, the terms “hereof,” “herein,” “hereunder” and similar
terms refer to this Agreement as a whole (including the exhibits hereto), and references herein to Articles, Sections and Exhibits refer
to Articles, Sections and Exhibits of this Agreement. The word “or” shall have the inclusive meaning represented by the phrase
 “and/or.” Except as otherwise indicated, all periods of time referred to herein shall include all Saturdays, Sundays and holidays;
provided, however, that if the date to perform the act or give any notice with respect to this Agreement shall fall on a
day other than a Business Day, such act or notice may be performed or given timely if performed or given on the next succeeding Business
Day. References to a Person are also to its permitted successors and assigns. The titles to Articles and headings of Sections contained
in this Agreement have been inserted for convenience of reference only and shall not be deemed to be a part of or to affect the meaning
or interpretation of this Agreement. The parties have participated jointly in the negotiation and drafting of this Agreement and, in the
event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as jointly drafted by the parties,
and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provision of this
Agreement.

 

    	 	6	 

     

    

 

ARTICLE II

 

REGISTRATION RIGHTS

 

2.1            Registration.

 

(a)            Request.
Any Holder(s) of Registrable Securities (collectively, the “Initiating Holder”) shall have the right (including,
for the avoidance of doubt, in connection with its rights pursuant to Section 2.7) to request that Kyndryl file a Registration
Statement with the SEC on the appropriate registration form for all or part of the Registrable Securities held by such Initiating Holder
by delivering a written request to Kyndryl specifying the aggregate number of shares of Registrable Securities such Initiating Holder
wishes to Register (a “Demand Registration”). Kyndryl shall (i) within five (5) days of the receipt of such
request, give written notice of such Demand Registration to all Holders of Registrable Securities (the “Kyndryl Notice”),
(ii) use its reasonable best efforts to prepare and file a Registration Statement as expeditiously as possible in respect of such
Demand Registration and in any event within thirty (30) days of receipt of the request, and (iii) use its reasonable best efforts
to cause such Registration Statement to become effective as expeditiously as possible. Kyndryl shall include in such Registration all
Registrable Securities that the Holders request to be included within the ten (10) days following their receipt of the Kyndryl Notice.

 

(b)            Limitations
of Demand Registrations. There shall be no limitation on the number of Demand Registrations pursuant to Section 2.1(a);
provided, however, that the Holder(s) may not require Kyndryl to effect a Demand Registration within sixty (60) days
after the effective date of a previous registration by Kyndryl, other than a Shelf Registration, effected pursuant to this Section 2.1.
In the event that any Person shall have received rights to Demand Registrations pursuant to Section 2.7 or Section 4.3,
and such Person shall have made a Demand Registration request, such request shall be treated as having been made by the Holder(s). The
Registrable Securities requested to be Registered pursuant to Section 2.1(a) must represent (i) an aggregate offering
price of Registrable Securities that is reasonably expected to equal at least $100,000,000 (or its equivalent if the Registrable Securities
are to be offered in an Exchange Offer) or (ii) all of the remaining Registrable Securities owned by the requesting Holder and its
Affiliates.

 

(c)            Effective
Registration. Kyndryl shall be deemed to have effected a Registration for purposes of Section 2.1(a) if the Registration
Statement is declared effective by the SEC or becomes effective upon filing with the SEC, and remains effective until the earlier of (i) the
date when all Registrable Securities thereunder have been Sold and (ii) (x) in case of a Registration Statement that is not
a Shelf Registration Statement, 60 days from the effective date of the Registration Statement or (y) 12 months from the effective
date of the Shelf Registration Statement (such period, as applicable, the “Registration Period”). No Registration shall
be deemed to have been effective if the conditions to closing specified in the underwriting agreement or dealer-manager agreement, if
any, entered into in connection with such Registration are not satisfied by reason of any member of the Kyndryl Group. If, during the
Registration Period, such Registration is interfered with by any stop order, injunction or other order or requirement of the SEC or other
Governmental Authority or the need to update or supplement the Registration Statement, the Registration Period shall be extended on a
day-for-day basis for any period the Holder is unable to complete an offering as a result of such stop order, injunction or other order
or requirement of the SEC or other Governmental Authority.

 

    	 	7	 

     

    

 

(d)            Underwritten
Offering; Exchange Offer. If the Initiating Holder so indicates at the time of its request pursuant to Section 2.1(a),
such offering of Registrable Securities shall be in the form of an Underwritten Offering or an Exchange Offer and Kyndryl shall include
such information in the Kyndryl Notice. In the event that the Initiating Holder intends to Sell the Registrable Securities by means of
an Underwritten Offering or Exchange Offer, the right of any Holder to include Registrable Securities in such Registration shall be conditioned
upon such Holder’s participation in such Underwritten Offering or Exchange Offer and the inclusion of such Holder’s Registrable
Securities in the Underwritten Offering or Exchange Offer.

 

(e)            Priority
of Securities in an Underwritten Offering. If the managing underwriter or underwriters of a proposed Underwritten Offering, including
an Underwritten Offering from a Shelf Registration, pursuant to this Section 2.1 informs the Holders with Registrable Securities
in the proposed Underwritten Offering in writing that, in its or their opinion, the number of Registrable Securities requested to be included
in such Underwritten Offering exceeds the number that can be Sold in such Underwritten Offering without being likely to have an adverse
effect on the price, timing or distribution of the Registrable Securities offered or the market for the Registrable Securities offered,
then the number of Registrable Securities to be included in such Underwritten Offering shall be reduced to such number that can be Sold
without such adverse effect based on the recommendation of the managing underwriter or underwriters and the Registrable Securities to
be included in such Underwritten Offering shall be: (i) first, Registrable Securities requested by IBM to be included in such Underwritten
Offering; (ii) second, Registrable Securities requested by all other Holders to be included in such Underwritten Offering on a pro
rata basis calculated based on the number of shares requested to be registered; and (iii) third, all other Registrable Securities
requested and otherwise eligible to be included in such Underwritten Offering (including Registrable Securities to be Sold for the account
of Kyndryl) on a pro rata basis calculated based on the number of shares requested to be registered. In the event the Initiating Holder
notifies Kyndryl that such Registration Statement shall be abandoned or withdrawn, such Holder shall not be deemed to have requested a
Demand Registration pursuant to Section 2.1(a), and Kyndryl shall not be deemed to have made a Demand Registration request
pursuant to Section 2.1(a) and Section 2.1(c).

 

(f)            Shelf
Registration. At any time after the date hereof when Kyndryl is eligible to Register the applicable Registrable Securities on Form S-3
(or a successor form) and Holders may request Demand Registrations, the requesting Holders may request Kyndryl to effect a Demand Registration
as a Shelf Registration. Any Holder of Registrable Securities included on a Shelf Registration shall have the right to request that Kyndryl
cooperate in a shelf takedown at any time, including an Underwritten Offering, by delivering a written request thereof to Kyndryl specifying
the number of shares of Registrable Securities such Holder wishes to include in the shelf takedown (“Takedown Notice”).
Kyndryl shall (i) within five (5) days of the receipt of a Takedown Notice for an Underwritten Offering, give written notice
of such Takedown Notice to all Holders of Registrable Securities included on such Shelf Registration (“Kyndryl Takedown Notice”),
and (ii) take all actions reasonably requested by such Holder, including the filing of a Prospectus supplement (“Takedown
Prospectus Supplement”) and the other actions described in Section 2.4, in accordance with the intended method of
distribution set forth in the Takedown Notice as expeditiously as possible. If the takedown is an Underwritten Offering, Kyndryl shall
include in such Underwritten Offering all Registrable Securities that that the Holders request to be included within the two (2) days
following their receipt of the Kyndryl Takedown Notice. If the takedown is an Underwritten Offering, the Registrable Securities requested
to be included in a shelf takedown must represent (i) an aggregate offering price of Registrable Securities that is reasonably expected
to equal at least $100,000,000 or (ii) all of the remaining Registrable Securities owned by the requesting Holder and its Affiliates.
Notwithstanding anything else to the contrary in this Agreement, the requirement to deliver a Kyndryl Takedown Notice and the piggyback
rights described in this Section 2.1(f) shall not apply to an Underwritten Offering that constitutes a Block Trade. There
shall be no limitations on the number of Underwritten Offerings pursuant to a Shelf Registration; provided, that in no event shall
Kyndryl be required to effect, pursuant to this Section 2.01(f), during any 90-day period, more than (A) two Block Trades
or (B) more than one Underwritten Offering that is not a Block Trade pursuant to a Takedown Notice (it being understood, for the
avoidance of doubt, that a Takedown Notice shall not count as a Demand Registration request for purposes of the limit set forth in Section 2.01(b)).

 

    	 	8	 

     

    

 

(g)            SEC
Form. Except as set forth in the next sentence, Kyndryl shall use its reasonable best efforts to cause Demand Registrations to be
Registered on Form S-3 (or any successor form), and if Kyndryl is not then eligible under the Securities Act to use Form S-3,
Demand Registrations shall be Registered on Form S-1 (or any successor form) or Form S-4 (in the case of an Exchange Offer).
If a Demand Registration is a Convertible or Exchange Registration, Kyndryl shall effect such Registration on the appropriate Form under
the Securities Act for such Registrations. Kyndryl shall use its reasonable best efforts to become eligible to use Form S-3 and,
after becoming eligible to use Form S-3, shall use its reasonable best efforts to remain so eligible. All Demand Registrations shall
comply with applicable requirements of the Securities Act and, together with each Prospectus included, filed or otherwise furnished by
Kyndryl in connection therewith, shall not contain any untrue statement of material fact or omit to state a material fact required to
be stated therein or necessary to make the statements therein not misleading.

 

2.2            Piggyback
Registrations.

 

(a)            Participation.
If Kyndryl proposes to file a Registration Statement under the Securities Act with respect to any offering of Kyndryl Common Stock for
its own account and/or for the account of any other Persons (other than a Registration (i) under Section 2.1 hereof,
(ii) pursuant to a Registration Statement on Form S-8 or Form S-4 or similar form that relates to a transaction subject
to Rule 145 under the Securities Act, (iii) pursuant to any form that does not include substantially the same information as
would be required to be included in a Registration Statement covering the Sale of Registrable Securities, (iv) in connection with
any dividend reinvestment or similar plan, (v) for the sole purpose of offering securities to another entity or its security holders
in connection with the acquisition of assets or securities of such entity or any similar transaction or (vi) in which the only Kyndryl
Common Stock being Registered is Kyndryl Common Stock issuable upon conversion of debt securities that are also being Registered) (a “Kyndryl
Public Sale”), then, as soon as practicable (but in no event less than fifteen (15) days prior to the proposed date of filing
such Registration Statement), Kyndryl shall give written notice of such proposed filing to each Holder, and such notice shall offer such
Holders the opportunity to Register under such Registration Statement such number of Registrable Securities as each such Holder may request
in writing (a “Piggyback Registration”).

 

    	 	9	 

     

    

 

Subject to Section 2.2(a) and
Section 2.2(c), Kyndryl shall include in such Registration Statement all such Registrable Securities that are requested to
be included therein within ten (10) days after the receipt of any such notice; provided, however, that if, at any
time after giving written notice of its intention to Register any securities and prior to the effective date of the Registration Statement
filed in connection with such Registration, Kyndryl shall determine for any reason not to Register or to delay Registration of such securities,
Kyndryl may, at its election, give written notice of such determination to each such Holder and, thereupon, (i) in the case of a
determination not to Register, shall be relieved of its obligation to Register any Registrable Securities in connection with such Registration,
without prejudice, however, to the rights of any Holder to request that such Registration be effected as a Demand Registration under
Section 2.1, and (ii) in the case of a determination to delay Registration, shall be permitted to delay Registering
any Registrable Securities for the same period as the delay in Registering such other shares of Kyndryl Common Stock. No Registration
effected under this Section 2.2 shall relieve Kyndryl of its obligation to effect any Demand Registration under Section 2.1.
If the offering pursuant to a Registration Statement pursuant to this Section 2.2 is to be an Underwritten Offering, then
each Holder making a request for a Piggyback Registration pursuant to this Section 2.2(a) shall, and Kyndryl shall use
reasonable best efforts to coordinate arrangements with the underwriters so that each such Holder may, participate in such Underwritten
Offering. If the offering pursuant to such Registration Statement is to be on any other basis, then each Holder making a request for
a Piggyback Registration pursuant to this Section 2.2(a) shall, and Kyndryl shall use reasonable best efforts to coordinate
arrangements so that each such Holder may, participate in such offering on such basis. Kyndryl’s filing of a Shelf Registration
shall not be deemed to be a Kyndryl Public Sale; provided, however, that the proposal to file any Prospectus supplement
filed pursuant to a Shelf Registration with respect to an offering of Kyndryl Common Stock for its own account and/or for the account
of any other Persons will be a Kyndryl Public Sale unless such offering qualifies for an exemption from the Kyndryl Public Sale definition
in this Section 2.2(a); provided, further that if Kyndryl files a Shelf Registration for its own account and/or
for the account of any other Persons, Kyndryl agrees that it shall use its reasonable best efforts to include in such Registration Statement
such disclosures as may be required by Rule 430B under the Securities Act in order to ensure that the Holders may be added to such
Shelf Registration at a later time through the filing of a Prospectus supplement rather than a post-effective amendment.

 

(b)            Right
to Withdraw. Each Holder shall have the right to withdraw such Holder’s request for inclusion of its Registrable Securities
in any Underwritten Offering pursuant to this Section 2.2 at any time prior to the execution of an underwriting agreement
with respect thereto by giving written notice to Kyndryl of such Holder’s request to withdraw and, subject to the preceding clause,
each Holder shall be permitted to withdraw all or part of such Holder’s Registrable Securities from a Piggyback Registration at
any time prior to the effective date thereof.

 

    	 	10	 

     

    

 

(c)            Priority
of Piggyback Registration. If the managing underwriter or underwriters of any proposed Underwritten Offering of a class of Registrable
Securities included in a Piggyback Registration informs Kyndryl and the Holders in writing that, in its or their opinion, the number of
securities of such class which such Holder and any other Persons intend to include in such Underwritten Offering exceeds the number which
can be Sold in such Underwritten Offering without being likely to have an adverse effect on the price, timing or distribution of the securities
offered or the market for the securities offered, then the securities to be included in such Underwritten Offering shall be reduced to
such number that can be Sold without such adverse effect based on the recommendation of the managing underwriter or underwriters and the
securities to be included in the Underwritten Offering shall be (i) first, all securities of Kyndryl or any other Persons for whom
Kyndryl is effecting the Underwritten Offering, as the case may be, proposes to Sell; (ii) second, Registrable Securities requested
by IBM to be included in such Underwritten Offering; (iii) third, Registrable Securities requested by all other Holders to be included
in such Underwritten Offering on a pro rata basis calculated based on the number of shares requested to be registered; and (iv) fourth,
all other securities requested and otherwise eligible to be included in such Underwritten Offering (including securities to be Sold for
the account of Kyndryl) on a pro rata basis calculated based on the number of shares requested to be registered.

 

2.3            Selection
of Underwriter(s), Etc. In any Underwritten Offering or Exchange Offer pursuant to Section 2.1 or Section 2.2
that is not an Kyndryl Public Sale, IBM or, in the event IBM is not participating in such Underwritten Offering or Exchange Offer,
the Holders of a majority of the outstanding Registrable Securities being included in the Underwritten Offering or Exchange Offer, shall
select the underwriter(s), dealer-manager(s), financial printer, solicitation and/or exchange agent (if any) and counsel to the Holder(s) for
such Underwritten Offering or Exchange Offer; provided, that IBM, or the Holders of a majority of the outstanding Registrable Securities,
as applicable, shall consult with Kyndryl and consider Kyndryl’s suggestions, if any, in good faith in connection with such selection.
In any Kyndryl Public Sale, Kyndryl shall select the underwriter(s), dealer-manager(s), financial printer, solicitation and/or exchange
agent (if any) and IBM or, in the event IBM is not participating in such Underwritten Offering or Exchange Offer, the Holders of a majority
of the outstanding Registrable Securities being included in the Kyndryl Public Sale shall select counsel to the Holder(s).

 

2.4            Registration
Procedures.

 

(a)            In
connection with the Registration and/or Sale of Registrable Securities pursuant to this Agreement, through an Underwritten Offering or
otherwise, Kyndryl shall use reasonable best efforts to effect or cause the Registration and the Sale of such Registrable Securities in
accordance with the intended methods of Sale thereof and:

 

(i)            prepare
and file the required Registration Statement including all exhibits and financial statements and, in the case of an Exchange Offer, any
document required under Rule 425 or Rule 165 with respect to such Exchange Offer (collectively, the “Ancillary Filings”)
required under the Securities Act to be filed therewith, and before filing with the SEC a Registration Statement or Prospectus, or any
amendments or supplements thereto, (A) furnish to the underwriters or dealer-managers, if any, and to the Holders, copies of all
documents prepared to be filed, which documents shall be subject to the review and comment of such underwriters or dealer-managers and
such Holders and their respective counsel, and provide such underwriters or dealers managers, if any, and such Holders and their respective
counsel reasonable time to review and comment thereon and (B) not file with the SEC any Registration Statement or Prospectus or amendments
or supplements thereto or any Ancillary Filing to which the Holders or the underwriters or dealer-managers, if any, shall reasonably object;

 

    	 	11	 

     

    

 

(ii)            except
in the case of a Shelf Registration or Convertible or Exchange Registration, prepare and file with the SEC such amendments and supplements
to such Registration Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement
effective and to comply with the provisions of the Securities Act with respect to the Sale of all of the Shares Registered thereon until
the earlier of (A) such time as all of such Shares have been Sold in accordance with the intended methods of Sale set forth in such
Registration Statement or (B) the expiration of nine (9) months after such Registration Statement becomes effective;

 

(iii)            in
the case of a Shelf Registration, prepare and file with the SEC such amendments and supplements to such Registration Statement and the
Prospectus used in connection therewith as may be necessary to keep such Registration Statement effective and to comply with the provisions
of the Securities Act with respect to the Sale of all Shares subject thereto for a period ending thirty-six (36) months after the effective
date of such Registration Statement;

 

(iv)            in
the case of a Convertible or Exchange Registration, prepare and file with the SEC such amendments and supplements to such Registration
Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement effective and to comply
with the provisions of the Securities Act with respect to the Sale of all of the Shares subject thereto until such time as the rules,
regulations and requirements of the Securities Act and the terms of any applicable convertible securities no longer require such Shares
to be Registered under the Securities Act;

 

(v)            notify
the participating Holders and the managing underwriter or underwriters or dealer-managers, if any, and (if requested) confirm such advice
in writing and provide copies of the relevant documents, as soon as reasonably practicable after notice thereof is received by Kyndryl
(A) when the applicable Registration Statement or any amendment thereto has been filed or becomes effective, when the applicable
Prospectus or any amendment or supplement to such Prospectus has been filed, or any Ancillary Filing has been filed, (B) of any written
comments by the SEC or any request by the SEC or any other Governmental Authority for amendments or supplements to such Registration Statement
or such Prospectus or any Ancillary Filing or for additional information, (C) of the issuance by the SEC of any stop order suspending
the effectiveness of such Registration Statement or any order preventing or suspending the use of any preliminary or final Prospectus
or any Ancillary Filing or the initiation or threatening of any proceedings for such purposes, (D) if, at any time, the representations
and warranties of Kyndryl in any applicable underwriting agreement or dealer-manager agreements cease to be true and correct in all material
respects, and (E) of the receipt by Kyndryl of any notification with respect to the suspension of the qualification of the Registrable
Securities for offering or Sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose;

 

    	 	12	 

     

    

 

(vi)            promptly
notify each selling Holder and the managing underwriter or underwriters or dealer-managers, if any, when Kyndryl becomes aware of the
occurrence of any event as a result of which the applicable Registration Statement or the Prospectus included in such Registration Statement
(as then in effect) or any Ancillary Filing contains any untrue statement of a material fact or omits to state a material fact necessary
to make the statements therein (in the case of such Prospectus and any preliminary Prospectus, in light of the circumstances under which
they were made) not misleading or, if for any other reason it shall be necessary during such time period to amend or supplement such Registration
Statement or Prospectus or any Ancillary Filing in order to comply with the Securities Act and, in either case as promptly as reasonably
practicable thereafter, prepare and file with the SEC, and furnish without charge to the selling Holder and the managing underwriter or
underwriters or dealer-managers, if any, an amendment or supplement to such Registration Statement or Prospectus or any Ancillary Filing
which will correct such statement or omission or effect such compliance;

 

(vii)            use
its reasonable best efforts to prevent or obtain the withdrawal of any stop order or other order suspending the use of any preliminary
or final Prospectus;

 

(viii)            promptly
incorporate in a Prospectus supplement or post-effective amendment such information as the managing underwriters or dealer-managers, if
any, and the Holders may reasonably request in order to permit the intended method of distribution of the Registrable Securities; and
make all required filings of such Prospectus supplement or post-effective amendment as soon as reasonably practicable after being notified
of the matters to be incorporated in such Prospectus supplement or post-effective amendment;

 

(ix)            furnish
to each selling Holder and each underwriter or dealer-manager, if any, without charge, as many conformed copies as such Holder or underwriter
or dealer-manager may reasonably request of the applicable Registration Statement and any amendment or post-effective amendment thereto,
including financial statements and schedules, all documents incorporated therein by reference and all exhibits (including those incorporated
by reference);

 

(x)            deliver
to each selling Holder and each underwriter or dealer-manager, if any, without charge, as many copies of the applicable Prospectus (including
each preliminary Prospectus) and any amendment or supplement thereto as such Holder or underwriter or dealer-manager may reasonably request
(it being understood that Kyndryl consents to the use of such Prospectus or any amendment or supplement thereto by each selling Holder
and the underwriters or dealer-managers, if any, in connection with the offering and Sale of the Registrable Securities covered by such
Prospectus or any amendment or supplement thereto) and such other documents as such selling Holder or underwriter or dealer-manager may
reasonably request in order to facilitate the Sale of the Registrable Securities by such Holder or underwriter or dealer-manager;

 

(xi)            on
or prior to the date on which the applicable Registration Statement is declared effective or becomes effective, use its reasonable best
efforts to register or qualify, and cooperate with each selling Holder, the managing underwriter or underwriters or dealer-managers, if
any, and their respective counsel, in connection with the registration or qualification of such Registrable Securities for offer and Sale
under the securities or “Blue Sky” laws of each state and other jurisdiction of the United States as any selling Holder
or managing underwriter or underwriters or dealer-managers, if any, or their respective counsel reasonably request, and in any foreign
jurisdiction mutually agreeable to Kyndryl and the participating Holders, in writing and do any and all other acts or things reasonably
necessary or advisable to keep such registration or qualification in effect for so long as such Registration Statement remains in effect
and so as to permit the continuance of Sales and dealings in such jurisdictions of the United States for so long as may be necessary to
complete the distribution of the Registrable Securities covered by the Registration Statement; provided that Kyndryl will not be required
to qualify generally to do business in any jurisdiction where it is not then so qualified or to take any action which would subject it
to taxation or general service of process in any such jurisdiction where it is not then so subject;

 

    	 	13	 

     

    

 

(xii)            in
connection with any Sale of Registrable Securities that will result in such securities no longer being Registrable Securities, cooperate
with each participating Holder and the managing underwriter or underwriters or dealer-managers, if any, to facilitate the timely preparation
and delivery of certificates representing Registrable Securities to be Sold and not bearing any restrictive Securities Act legends; and
to register such Registrable Securities in such denominations and such names as such selling Holder or the underwriters or dealer-managers,
if any, may request at least two (2) Business Days prior to such Sale of Registrable Securities; provided that Kyndryl may satisfy
its obligations hereunder without issuing physical stock certificates through the use of the Depository Trust Company’s Direct Registration
System;

 

(xiii)            cooperate
and assist in any filings required to be made with the Financial Industry Regulatory Authority and each securities exchange, if any, on
which any of Kyndryl’s securities are then listed or quoted and on each inter-dealer quotation system on which any of Kyndryl’s
securities are then quoted, and in the performance of any due diligence investigation by any underwriter or dealer-manager (including
any “qualified independent underwriter”) that is required to be retained in accordance with the rules and regulations
of each such exchange, and use its reasonable best efforts to cause the Registrable Securities covered by the applicable Registration
Statement to be registered with or approved by such other governmental agencies or authorities as may be necessary to enable the seller
or sellers thereof or the underwriter or underwriters or dealer-managers, if any, to consummate the Sale of such Registrable Securities;

 

(xiv)            not
later than the effective date of the applicable Registration Statement, provide a CUSIP number for all Registrable Securities and provide
the applicable transfer agent with printed certificates for the Registrable Securities which are in a form eligible for deposit with The
Depository Trust Company; provided that Kyndryl may satisfy its obligations hereunder without issuing physical stock certificates through
the use of the Depository Trust Company’s Direct Registration System;

 

(xv)            obtain
for delivery to and addressed to each selling Holder and to the underwriter or underwriters or dealer-managers, if any, opinions from
outside counsel and the general counsel for Kyndryl, in each case dated the effective date of the Registration Statement or, in the event
of an Underwritten Offering, the date of the closing under the underwriting agreement or, in the event of an Exchange Offer, the date
of the closing under the dealer-manager agreement or similar agreement or otherwise, and in each such case in customary form and content
for the type of Underwritten Offering or Exchange Offer, as applicable;

 

    	 	14	 

     

    

 

(xvi)            in
the case of an Underwritten Offering or Exchange Offer, obtain for delivery to and addressed to Kyndryl and the underwriter or underwriters
or dealer-managers and, to the extent requested, each participating Holder, a comfort letter from Kyndryl’s or other applicable
independent certified public accountants in customary form and content for the type of Underwritten Offering or Exchange Offer, dated
the date of execution of the underwriting agreement or dealer-manager agreement, or, if none, the date of commencement of the Exchange
Offer, and brought down to the closing, whether under the underwriting agreement or dealer-manager agreement, if applicable, or otherwise;

 

(xvii)            in
the case of an Exchange Offer that does not involve a dealer-manager, provide to each participating Holder such customary written representations
and warranties or other covenants or agreements as may be requested by any participating Holder comparable to those that would be included
in an underwriting agreement or dealer-manager agreement;

 

(xviii)            use
its reasonable best efforts to comply with all applicable rules and regulations of the SEC and make generally available to its security
holders, as soon as reasonably practicable, but no later than ninety (90) days after the end of the twelve (12)-month period beginning
with the first day of Kyndryl’s first quarter commencing after the effective date of the applicable Registration Statement, an earnings
statement satisfying the provisions of Section 11(a) of the Securities Act and the rules and regulations promulgated thereunder
and covering the period of at least twelve (12) months, but not more than eighteen (18) months, beginning with the first month after the
effective date of the Registration Statement;

 

(xix)            provide
and cause to be maintained a transfer agent and registrar for all Registrable Securities covered by the applicable Registration Statement
from and after a date not later than the effective date of such Registration Statement;

 

(xx)            cause
all Registrable Securities covered by the applicable Registration Statement to be listed on each securities exchange on which any of Kyndryl’s
securities are then listed or quoted and on each inter-dealer quotation system on which any of Kyndryl’s securities are then quoted;

 

(xxi)            provide
(A) each Holder participating in the Registration, (B) the underwriters (which term, for purposes of this Agreement, shall include
a Person deemed to be an underwriter within the meaning of Section 2(11) of the Securities Act), if any, of the Registrable Securities
to be Registered, (C) the Sale or placement agent therefor, if any, (D) the dealer-manager therefor, (E) counsel for such
underwriters or agent or dealer-manager, and (F) any attorney, accountant or other agent or representative retained by such Holder
or any such underwriter or dealer-manager, as selected by such Holder, the opportunity to participate in the preparation of such Registration
Statement, each Prospectus included therein or filed with the SEC, and each amendment or supplement thereto, and to require the insertion
therein of material, furnished to Kyndryl in writing, which in the reasonable judgment of such Holder(s) and their counsel should
be included; and for a reasonable period prior to the filing of such Registration Statement, upon receipt of such confidentiality agreements
as Kyndryl may reasonably request, make available upon reasonable notice at reasonable times and for reasonable periods for inspection
by the parties referred to in (A) through (F) above, all pertinent financial and other records, pertinent corporate and other
documents and properties of Kyndryl that are available to Kyndryl, and cause all of Kyndryl’s officers, directors and employees
and the independent public accountants who have certified its financial statements to make themselves available at reasonable times and
for reasonable periods to discuss the business of Kyndryl and to supply all information available to Kyndryl reasonably requested by any
such Person in connection with such Registration Statement as shall be necessary to enable them to exercise their due diligence responsibility,
subject to the foregoing;

 

    	 	15	 

     

    

 

(xxii)            to
cause the executive officers of Kyndryl to participate in customary “road show” presentations that may be reasonably requested
by the managing underwriter or underwriters or dealer-managers in any Underwritten Offering or Exchange Offer and otherwise to facilitate,
cooperate with, and participate in each proposed offering contemplated herein and customary selling efforts related thereto;

 

(xxiii)            comply
with all requirements of the Securities Act, Exchange Act and other applicable laws, rules and regulations, as well as applicable
stock exchange rules; and

 

(xxiv)            take
all other customary steps reasonably necessary to effect the Registration, offering and Sale of the Registrable Securities.

 

(b)            As
a condition precedent to any Registration hereunder, Kyndryl may require each Holder as to which any Registration is being effected to
furnish to Kyndryl such information regarding the distribution of such securities and such other information relating to such Holder,
its ownership of Registrable Securities and other matters as Kyndryl may from time to time reasonably request in writing. Each such Holder
agrees to furnish such information to Kyndryl and to cooperate with Kyndryl as reasonably necessary to enable Kyndryl to comply with the
provisions of this Agreement.

 

(c)            IBM
agrees, and any other Holder agrees by acquisition of such Registrable Securities, that, upon receipt of any written notice from Kyndryl
of the occurrence of any event of the kind described in Section 2.4(a)(vi), such Holder will forthwith discontinue the Sale
of Registrable Securities pursuant to such Registration Statement until such Holder’s receipt of the copies of the supplemented
or amended Prospectus contemplated by Section 2.4(a)(vi), or until such Holder is advised in writing by Kyndryl that the use
of the Prospectus may be resumed, and if so directed by Kyndryl, such Holder will deliver to Kyndryl (at Kyndryl’s expense) all
copies, other than permanent file copies then in such Holder’s possession, of the Prospectus covering such Registrable Securities
current at the time of receipt of such notice. In the event Kyndryl shall give any such notice, the period during which the applicable
Registration Statement is required to be maintained effective shall be extended by the number of days during the period from and including
the date of the giving of such notice to and including the date when each seller of Registrable Securities covered by such Registration
Statement either receives the copies of the supplemented or amended Prospectus contemplated by Section 2.4(a)(vi) or
is advised in writing by Kyndryl that the use of the Prospectus may be resumed.

 

2.5            Holdback
Agreements. To the extent requested in writing by the managing underwriter or underwriters of any Underwritten Offering, Kyndryl agrees
not to, and shall exercise reasonable best efforts to obtain agreements (in the underwriters’ customary form) from its directors,
executive officers and any beneficial owner or owners of five percent (5%) or more of Kyndryl Common Stock that has a representative on
the board of directors of Kyndryl not to, directly or indirectly offer, Sell, pledge, contract to Sell (including any short Sale), grant
any option to purchase or otherwise Sell any equity securities of Kyndryl or enter into any hedging transaction relating to any equity
securities of Kyndryl during the ninety (90) days beginning on pricing date of such Underwritten Offering (except as part of such Underwritten
Offering or any Distribution or pursuant to registrations on Form S-8 or S-4 or any successor forms thereto) unless the managing
underwriter or underwriters otherwise agree to a shorter period.

 

    	 	16	 

     

    

 

2.6            Underwritten
Offerings; Exchange Offers. If requested by the managing underwriters for any Underwritten Offering or dealer-managers for any Exchange
Offer, Kyndryl shall enter into an underwriting agreement or dealer-manager agreement with such underwriters or dealer-managers for such
offering; provided, however, that no Holder shall be required to make any representations or warranties to Kyndryl or the
underwriters or dealer-managers (other than representations and warranties regarding such Holder and such Holder’s intended method
of distribution) or to undertake any indemnification obligations to Kyndryl or the underwriters or dealer-managers with respect thereto,
except as otherwise provided in Section 2.9 hereof.

 

2.7            Convertible
or Exchange Registration; Registration Rights with Participating Banks.

 

(a)            If
any Holder of Registrable Securities offers any options, rights, warrants or other securities issued by it or any other Person that are
offered with, convertible into or exercisable or exchangeable for any Registrable Securities, the Registrable Securities underlying such
options, rights, warrants or other securities shall be eligible for Registration pursuant to Section 2.1 and Section 2.2
hereof (a “Convertible or Exchange Registration”).

 

(b)            If
one or more members of the IBM Group decides to engage, directly or indirectly, in an Exchange with one or more Participating Banks, Kyndryl
shall, upon IBM’s request, enter into a registration rights agreement with the Participating Banks in connection with such Exchange,
as applicable, on terms and conditions consistent with this Agreement (other than the voting provisions contained in Article III
hereof) and reasonably satisfactory to Kyndryl and the IBM Group.

 

2.8            Registration
Expenses Paid By Kyndryl. In the case of any Registration of Registrable Securities required pursuant to this Agreement (including
any Registration that is delayed or withdrawn) or proposed Underwritten Offering pursuant to this Agreement, Kyndryl shall pay all Registration
Expenses regardless of whether the Registration Statement becomes effective or the Underwritten Offering is completed.

 

    	 	17	 

     

    

 

2.9            Indemnification.

 

(a)            Indemnification
by Kyndryl. Kyndryl agrees to indemnify and hold harmless, to the full extent permitted by law, each Holder, such Holder’s Affiliates
and their respective officers, directors, employees, advisors, and agents and each Person who controls (within the meaning of the Securities
Act or the Exchange Act) such Persons from and against any and all losses, claims, damages, liabilities (or actions in respect thereof,
whether or not such indemnified party is a party thereto) and expenses, joint or several (including reasonable costs of investigation
and legal expenses) (each, a “Loss” and collectively “Losses”) arising out of or based upon (i) any
untrue or alleged untrue statement of a material fact contained in any Registration Statement under which the Sale of such Registrable
Securities was Registered under the Securities Act (including any final or preliminary Prospectus contained therein or any amendment thereof
or supplement thereto or any documents incorporated by reference therein), or any such statement made in any free writing prospectus (as
defined in Rule 405 under the Securities Act) that Kyndryl has filed or is required to file pursuant to Rule 433(d) under
the Securities Act, or (ii) any omission or alleged omission to state therein a material fact required to be stated therein or necessary
to make the statements therein (in the case of a Prospectus, preliminary Prospectus or free writing prospectus, in light of the circumstances
under which they were made) not misleading; provided, however, that Kyndryl shall not be liable to any particular indemnified
party in any such case to the extent that any such Loss arises out of or is based upon an untrue statement or alleged untrue statement
or omission or alleged omission made in any such Registration Statement in reliance upon and in conformity with written information furnished
to Kyndryl by such indemnified party expressly for use in the preparation thereof. This indemnity shall be in addition to any liability
Kyndryl may otherwise have. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf
of such Holder or any indemnified party and shall survive the transfer of such securities by such Holder.

 

(b)            Indemnification
by the Selling Holder. Each selling Holder agrees (severally and not jointly) to indemnify and hold harmless, to the full extent permitted
by law, Kyndryl, its directors, officers, employees, advisors, and agents and each Person who controls Kyndryl (within the meaning of
the Securities Act and the Exchange Act) from and against any Losses arising out of or based upon (i) any untrue or alleged untrue
statement of a material fact contained in any Registration Statement under which the Sale of such Registrable Securities was Registered
under the Securities Act (including any final or preliminary Prospectus contained therein or any amendment thereof or supplement thereto
or any documents incorporated by reference therein), or any such statement made in any free writing prospectus that Kyndryl has filed
or is required to file pursuant to Rule 433(d) under the Securities Act, or (ii) any omission or alleged omission to state
therein a material fact required to be stated therein or necessary to make the statements therein (in the case of a Prospectus, preliminary
Prospectus or free writing prospectus, in light of the circumstances under which they were made) not misleading to the extent, but, in
each case (i) or (ii), only to the extent, that such untrue statement or omission is made in reliance upon and conformity with any
information furnished in writing by such selling Holder to Kyndryl specifically for inclusion in such Registration Statement, Prospectus,
preliminary Prospectus or free writing prospectus. In no event shall the liability of any selling Holder hereunder be greater in amount
than the dollar amount of the net proceeds received by such Holder (or the fair value of the security received in an Exchange Offer) under
the Sale of the Registrable Securities giving rise to such indemnification obligation. This indemnity shall be in addition to any liability
the selling Holder may otherwise have. Such indemnity shall remain in full force and effect regardless of any investigation made by or
on behalf of Kyndryl or any indemnified party.

 

    	 	18	 

     

    

 

(c)            Conduct
of Indemnification Proceedings. Any Person entitled to indemnification hereunder will (i) give prompt written notice to the indemnifying
party of any claim with respect to which it seeks indemnification (provided that any delay or failure to so notify the indemnifying party
shall relieve the indemnifying party of its obligations hereunder only to the extent that it is materially prejudiced by reason of such
delay or failure) and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory
to the indemnified party; provided, however, that any Person entitled to indemnification hereunder shall have the right
to select and employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall
be at the expense of such Person unless (i) the indemnifying party has agreed in writing to pay such fees or expenses, (ii) the
indemnifying party shall have failed to assume the defense of such claim within a reasonable time after receipt of notice of such claim
from the Person entitled to indemnification hereunder and employ counsel reasonably satisfactory to such Person, (iii) the indemnified
party has reasonably concluded (based on advice of counsel) that there may be legal defenses available to it or other indemnified parties
that are different from or in addition to those available to the indemnifying party, or (iv) in the reasonable judgment of any such
Person, based upon advice of its counsel, a conflict of interest may exist between such Person and the indemnifying party with respect
to such claims (in which case, if the Person notifies the indemnifying party in writing that such Person elects to employ separate counsel
at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf
of such Person). If such defense is not assumed by the indemnifying party, the indemnifying party will not be subject to any liability
for any settlement made without its consent, but such consent may not be unreasonably withheld, conditioned or delayed. If the indemnifying
party assumes the defense, the indemnifying party shall not have the right to settle such action without the consent of the indemnified
party, which consent may not be unreasonably withheld, conditioned or delayed. No indemnifying party shall consent to entry of any judgment
or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified
party of an unconditional release from all liability in respect to such claim or litigation. It is understood that the indemnifying party
or parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable
fees, disbursements and other charges of more than one separate firm at any one time (in addition to local counsel) from all such indemnified
party or parties unless (x) the employment of more than one counsel has been authorized in writing by the indemnified party or parties,
(y) an indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available to it that
are different from or in addition to those available to the other indemnified parties or (z) a conflict or potential conflict exists
or may exist (based on advice of counsel to an indemnified party) between such indemnified party and the other indemnified parties, in
each of which cases the indemnifying party shall be obligated to pay the reasonable fees and expenses of such additional counsel or counsels.

 

    	 	19	 

     

    

 

(d)            Contribution.
If for any reason the indemnification provided for in Section 2.9(a) or Section 2.9(b) is unavailable
to an indemnified party or insufficient to hold it harmless as contemplated by Section 2.9(a) or Section 2.9(b),
then the indemnifying party shall contribute to the amount paid or payable by the indemnified party as a result of such Loss in such proportion
as is appropriate to reflect the relative fault of the indemnifying party on the one hand and the indemnified party on the other hand.
The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material
fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or the indemnified
party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such untrue statement
or omission. Notwithstanding anything in this Section 2.9(d) to the contrary, no indemnifying party (other than Kyndryl)
shall be required pursuant to this Section 2.9(d) to contribute any amount in excess of the amount by which the net proceeds
received by such indemnifying party from the Sale of Registrable Securities in the offering to which the Losses of the indemnified parties
relate (before deducting expenses, if any) exceeds the amount of any damages which such indemnifying party has otherwise been required
to pay by reason of such untrue statement or omission. The parties hereto agree that it would not be just and equitable if contribution
pursuant to this Section 2.9(d) were determined by pro rata allocation or by any other method of allocation that does
not take account of the equitable considerations referred to in this Section 2.9(d). Notwithstanding the provisions of this
Section 2.9(d), no selling Holder hereunder shall be required to contribute any amount in excess of the dollar amount of the
net proceeds received by such Holder (or the fair value of the security received in an Exchange Offer) under the Sale of the Registrable
Securities giving rise to such indemnification obligation. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. The amount
paid or payable by an indemnified party hereunder shall be deemed to include, for purposes of this Section 2.9(d), any legal
or other expenses reasonably incurred by such indemnified party in connection with investigating, preparing to defend or defending against
or appearing as a third party witness in respect of, or otherwise incurred in connection with, any such loss, claim, damage, expense,
liability, action, investigation or proceeding. If indemnification is available under this Section 2.9, the indemnifying parties
shall indemnify each indemnified party to the full extent provided in Section 2.9(a) and Section 2.9(b) hereof
without regard to the relative fault of said indemnifying parties or indemnified party.

 

    	 	20	 

     

    

 

2.10            Reporting
Requirements; Rule 144. Until the expiration or termination of this Agreement in accordance with its terms, Kyndryl shall be
and remain in compliance with the periodic filing requirements imposed under the SEC’s rules and regulations, including the
Exchange Act, and any other applicable laws or rules, and shall timely file such information, documents and reports as the SEC may require
or prescribe under Section 13 or 15(d) (whichever is applicable) of the Exchange Act. If Kyndryl is not required to file such
reports, it will, upon the request of any Holder, make publicly available such necessary information for so long as necessary to permit
Sales pursuant to Rule 144 or Regulation S under the Securities Act, and it will take such further action as any Holder may reasonably
request, all to the extent required from time to time to enable such Holder to Sell Registrable Securities without Registration under
the Securities Act within the limitation of the exemptions provided by (a) Rule 144 or Regulation S under the Securities Act,
as such Rules may be amended from time to time, or (b) any rule or regulation hereafter adopted by the SEC. From and after
the date hereof through the first anniversary of the date upon which no Holder owns any Registrable Securities, Kyndryl shall forthwith
upon request furnish any Holder (i) a written statement by Kyndryl as to whether it has complied with such requirements and, if not,
the specifics thereof, (ii) a copy of the most recent annual or quarterly report of Kyndryl, and (iii) such other reports and
documents filed by Kyndryl with the SEC as such Holder may reasonably request in availing itself of an exemption for the Sale of Registrable
Securities without registration under the Securities Act.

 

2.11            Other
Registration Rights. Kyndryl shall not grant to any Persons the right to request Kyndryl to Register any equity securities of Kyndryl,
or any securities convertible or exchangeable into or exercisable for such securities, whether pursuant to “demand,” “piggyback,”
or other rights, unless such rights are subject and subordinate to the rights of the Holders under this Agreement.

 

    	 	21	 

     

    

 

ARTICLE III

 

VOTING RESTRICTIONS

 

3.1            Voting
of Kyndryl Common Stock.

 

(a)            From
the date of the Distribution until the date that the IBM Group ceases to own any Retained Shares, IBM shall, and shall cause each
member of the IBM Group to (in each case, to the extent that they own any Retained Shares), be present, in person or by proxy, at each
and every Kyndryl stockholder meeting, and otherwise to cause all Retained Shares owned by them to be counted as present for purposes
of establishing a quorum at any such meeting, and to vote or consent on any matter (including waivers of contractual or statutory rights),
or cause to be voted or consented on any such matter, all such Retained Shares in proportion to the votes cast by the other holders of
Kyndryl Common Stock on such matter.

 

(b)            From
the date of the Distribution until the date that the IBM Group ceases to own any Retained Shares, IBM hereby grants, and shall cause
each member of the IBM Group (in each case, to the extent that they own any Retained Shares) to grant, an irrevocable proxy, which shall
be deemed coupled with an interest sufficient in law to support an irrevocable proxy to Kyndryl or its designees, to vote, with respect
to any matter (including waivers of contractual or statutory rights), all Retained Shares owned by them, in proportion to the votes cast
by the other holders of Kyndryl Common Stock on such matter; provided that (i) such proxy shall automatically be revoked as to a
particular Retained Share upon any Sale of such Retained Share from a member of the IBM Group to a Person other than a member of the IBM
Group and (ii) nothing in this Section 3.1(b) shall limit or prohibit any such Sale.

 

(c)            IBM
acknowledges and agrees (on behalf of itself and each member of the IBM Group) that Kyndryl will be irreparably damaged in the event any
of the provisions of this Article III are not performed by IBM in accordance with their terms or are otherwise breached. Accordingly,
it is agreed that Kyndryl shall be entitled to an injunction to prevent breaches of this Article III and to specific enforcement
of the provisions of this Article III in any action instituted in any court of the United States or any state having subject
matter jurisdiction over such action.

 

ARTICLE IV

 

MISCELLANEOUS

 

4.1            Term.
This Agreement shall terminate upon such time as there are no Registrable Securities, except for the provisions of Section 2.8
and Section 2.9 and all of this Article IV, which shall survive any such termination.

 

    	 	22	 

     

    

 

4.2            Notices.
All notices or other communications under this Agreement shall be in writing and shall be deemed to be duly given (a) when delivered
in person, (b) on the date received, if sent by a nationally recognized delivery or courier service, (c) upon written confirmation
of receipt after transmittal by electronic mail or (d) upon the earlier of confirmed receipt or the fifth (5th) business day following
the date of mailing if sent by registered or certified mail, return receipt requested, postage prepaid and addressed as follows:

 

To IBM:

 

International Business Machines Corporation

One New Orchard Road

Armonk, NY 10504

	Attn:	General Manager, Corporate Development and Strategy

 

with a copy to:

 

Paul, Weiss, Rifkind, Wharton &
Garrison LLP

1285 Avenue of the Americas

New York, NY 10019-6064

	Attn:	Scott A. Barshay
	     	Steven J. Williams
	     	Laura C. Turano
	Email:	sbarshay@paulweiss.com
	     	swilliams@paulweiss.com
	     	lturano@paulweiss.com

 

To Kyndryl:

 

Kyndryl Holdings, Inc.

One Vanderbilt Avenue, 15th Floor

New York, NY 10017

	Attn:	Thomas P. Hagen, Associate General Counsel

 

Either party may, by notice to the other party, change the address
and identity of the Person to which such notices and copies of such notices are to be given. Each party agrees that nothing in this Agreement
shall affect the other party’s right to serve process in any other manner permitted by law (including pursuant to the rules for
foreign service of process authorized by the Hague Convention).

 

4.3            Successors,
Assigns and Transferees.

 

(a)            The
provisions of this Agreement and the obligations and rights hereunder shall be binding upon, inure to the benefit of and be enforceable
by (and against) the parties and their respective successors and permitted assigns. Kyndryl may assign this Agreement at any time in connection
with a Sale or acquisition of Kyndryl, whether by merger, consolidation, Sale of all or substantially all of Kyndryl’s assets, or
similar transaction, without the consent of the Holders; provided that the successor or acquiring Person agrees in writing to assume all
of Kyndryl’s rights and obligations under this Agreement. IBM may assign this Agreement to any member of the IBM Group or at any
time in connection with a sale or acquisition of IBM, whether by merger, consolidation, sale of all or substantially all of IBM’s
assets, or similar transaction, without the consent of Kyndryl.

 

    	 	23	 

     

    

 

(b)            In
connection with the Sale of Registrable Securities, IBM may assign its Registration-related rights and obligations under this Agreement
relating to such Registrable Securities to the following transferees in such Sale: (i) a member of the IBM Group to which Registrable
Securities are Sold, (ii) one or more Participating Banks to which Registrable Securities are Sold, (iii) any other transferee
to which Registrable Securities are Sold, if Kyndryl provides prior written consent to the transfer of such Registration-related rights
and obligations along with the Sale of Registrable Securities or (iv) any other transferee that acquires at least five percent (5%)
of the outstanding shares of Kyndryl Common Stock immediately following the completion of the Distribution; provided, that in the
case of clauses (i), (ii), (iii) or (iv), (x) Kyndryl is given written notice prior to or at the time of such Sale stating the
name and address of the transferee and identifying the securities with respect to which the Registration-related rights and obligations
are being Sold and (y) the transferee executes a counterpart in the form attached hereto as Exhibit A and delivers the same
to Kyndryl (any such transferee in such Sale, a “Transferee”). In connection with the Sale of Registrable Securities,
a Transferee or Subsequent Transferee (as defined below) may assign its Registration-related rights and obligations under this Agreement
relating to such Registrable Securities to the following subsequent transferees: (A) an Affiliate of such Transferee to which Registrable
Securities are Sold, (B) any subsequent transferee to which Registrable Securities are Sold, if Kyndryl provides prior written consent
to the transfer of such Registration-related rights and obligations along with the Sale of Registrable Securities or (C) any other
subsequent transferee that acquires at least five percent (5%) of the outstanding shares of Kyndryl Common Stock immediately following
the completion of the Distribution; provided, that in the case of clauses (A), (B) or (C), (x) Kyndryl is given written notice
prior to or at the time of such Sale stating the name and address of the subsequent transferee and identifying the securities with respect
to which the Registration-related rights and obligations are being assigned and (y) the subsequent transferee executes a counterpart
in the form attached hereto as Exhibit A and delivers the same to Kyndryl (any such subsequent transferee, a “Subsequent
Transferee”).

 

4.4            GOVERNING
LAW; NO JURY TRIAL.

 

(a)            This
Agreement and any disputes relating to, arising out of or resulting from this Agreement, including to its execution, performance, or enforcement,
shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise
govern under applicable principles of conflicts of laws thereof.

 

(b)            In
the event of any claim, controversy, demand or request for relief of any kind arising out of, in connection with, or in relation to the
interpretation, performance, nonperformance, validity or breach of this Agreement or otherwise arising out of or related to this Agreement
or the transactions contemplated hereby, including any Action based on contract, tort, equity, statute, regulation or constitution (each,
a “Dispute” and collectively, “Disputes”), the party raising the Dispute shall give written notice of
the Dispute (a “Dispute Notice”), and the general counsels of the parties (or such other individuals designated by
the respective general counsels) and/or the executive officers designated by the parties shall negotiate for a reasonable period of time
to settle such Dispute; provided, that such reasonable period shall not, unless otherwise agreed by the parties in writing, exceed ninety
(90) days (the “Negotiation Period”) from the time of receipt of the Dispute Notice; provided, further,
that in the event of any arbitration in accordance with Section 4.4(c) hereof, the parties shall not assert the defenses
of statute of limitations, laches and any other defense, in each such case based on the passage of time during the Negotiation Period,
and any contractual time period or deadline under this Agreement relating to such Dispute occurring after the Dispute Notice is received
shall not be deemed to have passed until such Dispute has been resolved.

 

    	 	24	 

     

    

 

(c)            If
the Dispute has not been resolved for any reason after the Negotiation Period, such Dispute may be submitted by either party to final
and binding arbitration administered in accordance with the Commercial Arbitration Rules of the American Arbitration Association
(“AAA”) then in effect (the “Rules”), except as modified herein.

 

(i)            The
arbitration shall be conducted by a three-member arbitral tribunal (the “Arbitral Tribunal”). The claimant shall nominate
one arbitrator in accordance with the Rules, and the respondent shall nominate one arbitrator in accordance with the Rules within
twenty-one days (21) after the appointment of the first arbitrator. The third arbitrator, who shall serve as chair of the Arbitral Tribunal,
shall be jointly nominated by the two party-nominated arbitrators within twenty-one (21) days of the confirmation of the appointment of
the second arbitrator. If any arbitrator is not appointed within the time limit provided herein, such arbitrator shall be appointed by
the AAA in accordance with the listing, striking and ranking procedure in the Rules.

 

(ii)            The
arbitration shall be held, and the award shall be rendered, in New York, New York, in the English language.

 

(iii)            For
the avoidance of doubt, by submitting their Dispute to arbitration under the Rules, the parties expressly agree that all issues of arbitrability,
including all issues concerning the propriety and timeliness of the commencement of the arbitration, the jurisdiction of the Arbitral
Tribunal (including the scope of this agreement to arbitrate and the extent to which a Dispute is within that scope), and the procedural
conditions for arbitration, shall be finally and solely determined by the Arbitral Tribunal.

 

(iv)            Without
derogating from Section 4.4(c)(v), Section 4.5, or Section 4.6 below, the Arbitral Tribunal shall
have the full authority to grant any pre-arbitral injunction, pre-arbitral attachment, interim or conservatory measure or other order
in aid of arbitration proceedings (“Interim Relief”). The parties shall exclusively submit any application for Interim
Relief to only: (A) the Arbitral Tribunal; or (B) prior to the constitution of the Arbitral Tribunal, an emergency arbitrator
appointed in the manner provided for in the Rules. Any Interim Relief so issued shall, to the extent permitted by applicable law, be deemed
a final arbitration award for purposes of enforceability, and, moreover, shall also be deemed a term and condition of this Agreement subject
to specific performance in Section 4.5 below. The foregoing procedures shall constitute the exclusive means of seeking Interim
Relief (subject, for the avoidance of doubt, to Section 4.5 and Section 4.6 below), provided, however,
that (i) the Arbitral Tribunal shall have the power to continue, review, vacate or modify any Interim Relief granted by an Emergency
Arbitrator and (ii) in the event an Emergency Arbitrator or the Arbitral Tribunal issues an order granting, denying or otherwise
addressing Interim Relief (a “Decision on Interim Relief”), any party may apply to enforce or require specific performance
of such Decision on Interim Relief in any court of competent jurisdiction.

 

    	 	25	 

     

    

 

(v)            The
Arbitral Tribunal shall have the power to grant any remedy or relief that is in accordance with the terms of this Agreement, including
specific performance and temporary or final injunctive relief, provided, however, that the Arbitral Tribunal shall have
no authority or power to limit, expand, alter, amend, modify, revoke or suspend any condition or provision of this Agreement, nor any
right or power to award punitive, exemplary, enhanced or treble damages.

 

(vi)            The
Arbitral Tribunal shall have the power to allocate the costs and fees of the arbitration, including reasonable attorneys’ fees and
costs as well as those costs and fees addressed in the Rules, between the parties in the manner it deems fit.

 

(vii)            Without
derogating from Section 4.5 or Section 4.6 below, arbitration under this Section 4.4 shall be the
sole and exclusive remedy for any Dispute, and any award rendered thereby shall be final and binding upon the parties as from the date
rendered. Judgment on the award rendered by the Arbitral Tribunal may be entered in any state or federal court within the State of Delaware
(which the parties hereby agree have jurisdiction over them to enforce any such award) and any other court having jurisdiction thereof,
including any court having jurisdiction over the relevant Party or its Assets.

 

4.5            Specific
Performance. Notwithstanding anything to the contrary in this Agreement (including, for the avoidance of doubt, Section 4.4(b) and
Section 4.4(c)), in the event of any actual or threatened default in, or breach of, any of the terms, conditions and provisions
of this Agreement, the affected party shall have the right, without first pursuing the procedures provided for in Sections 4.4(b) and
Section 4.4(c), to specific performance, declaratory relief and injunctive or other equitable relief (on a permanent, emergency,
temporary, preliminary or interim basis) of its rights under this Agreement, in addition to any and all other rights and remedies at law
or in equity, and all such rights and remedies shall be cumulative. The other party shall not oppose the granting of such relief on the
basis that money damages are an adequate remedy. The parties agree that the remedies at law for any breach or threatened breach hereof,
including monetary damages, are inadequate compensation for any loss and that any defense in any action for specific performance that
a remedy at law would be adequate is waived. Any requirements for the securing or posting of any bond or similar security with such remedy
are waived.

 

4.6            Venue
for Injunctive Relief and Specific Performance Claims. Notwithstanding anything to the contrary in this Agreement (including, for
the avoidance of doubt, Section 4.4(b) and Section 4.4(c)), an affected party may bring any claim for specific
performance, declaratory relief and injunctive or other equitable relief (on a permanent, emergency, temporary, preliminary or interim
basis) under Section 4.5 of this Agreement (a “Chosen Court Claim”) either (a) pursuant to the procedures
contained in Section 4.4(b) and Section 4.4(c); or (b) at the affected party’s sole discretion,
in the Delaware Court of Chancery (or, if the Delaware Court of Chancery shall be unavailable, any Delaware State court or the federal
court sitting in the State of Delaware) (the “Chosen Courts”).  The parties irrevocably consent and agree, on
behalf of themselves and their Affiliates, to the jurisdiction, forum and venue of the Chosen Courts for a Chosen Court Claim, and agree
that they shall not assert, and shall hereby waive, any claim or right or defense that they are not subject to the jurisdiction of the
Chosen Courts, that the venue is improper, that the forum is inconvenient, that the Chosen Court Claim should instead be arbitrated by
their agreement or operation of law, or any similar objection, claim or argument.

 

    	 	26	 

     

    

 

4.7            Headings.
The article, section and paragraph headings contained in this Agreement are inserted for the convenience of reference only and are not
intended to be a part of or to affect the meaning or interpretation of this Agreement.

 

4.8            Severability.
If any provision of this Agreement or the application thereof to any Person or circumstance is determined by a court or arbitrator of
competent jurisdiction to be invalid, void or unenforceable, the remaining provisions hereof, or the application of such provision to
Persons or circumstances, or in jurisdictions other than those as to which it has been held invalid or unenforceable, shall remain in
full force and effect and shall in no way be affected, impaired or invalidated thereby, so long as the economic or legal substance of
the transactions contemplated hereby is not affected in any manner materially adverse to either party. Upon any such determination, any
such provision, to the extent determined to be invalid, void or unenforceable, shall be deemed replaced by a provision that such court
determines is valid and enforceable and that comes closest to expressing the intention of the invalid, void or unenforceable provision.

 

4.9            Amendment;
Waiver.

 

(a)            This
Agreement may not be amended or modified and waivers and consents to departures from the provisions hereof may not be given, except by
an instrument or instruments in writing making specific reference to this Agreement and signed by Kyndryl and the Holders of a majority
of the Registrable Securities; provided that if IBM or any of its Affiliates owns Registrable Securities, no amendment to or waiver of
any provision in this Agreement will be effected without the written consent of IBM if such amendment or waiver adversely affects the
rights of IBM or such Affiliates of IBM.

 

(b)            No
failure to exercise and no delay in exercising, on the part of any party, any right, remedy, power or privilege hereunder shall operate
as a waiver hereof or thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder or thereunder
preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.

 

4.10            Registrations,
Exchanges, etc. Notwithstanding anything to the contrary that may be contained in this Agreement, the provisions of this Agreement
shall apply to the full extent set forth herein with respect to (a) any shares of Kyndryl Common Stock, now or hereafter authorized
to be issued, (b) any and all securities of Kyndryl into which the shares of Kyndryl Common Stock are converted, exchanged or substituted
in any recapitalization or other capital reorganization by Kyndryl and (c) any and all securities of any kind whatsoever of Kyndryl
or any successor or permitted assign of Kyndryl (whether by merger, consolidation, Sale of assets or otherwise) which may be issued on
or after the date hereof in respect of, in conversion of, in exchange for or in substitution of, the shares of Kyndryl Common Stock, and
shall be appropriately adjusted for any stock dividends, or other distributions, stock splits or reverse stock splits, combinations, recapitalizations,
mergers, consolidations, exchange offers or other reorganizations occurring after the date hereof.

 

    	 	27	 

     

    

 

4.11            Further
Assurances. In addition to the actions specifically provided for elsewhere in this Agreement, but subject to the express limitations
of this Agreement, each of the parties shall use reasonable best efforts, prior to, on and after the Distribution, to take, or cause to
be taken, all actions, and to do, or cause to be done, all things, reasonably necessary, proper or advisable under applicable laws and
agreements to consummate, make effective, the transactions contemplated by this Agreement.

 

4.12            Counterparts.
This Agreement may be executed in one or more counterparts, all of which counterparts shall be considered one and the same agreement,
and shall become effective when one or more counterparts have been signed by each party and delivered to the other party. This Agreement
may be executed by facsimile or PDF signature and scanned and exchanged by electronic mail, and such facsimile or PDF signature or scanned
and exchanged copies shall constitute an original for all purposes.

 

[The remainder of page intentionally
left blank. Signature page follows.]

 

    	 	28	 

     

    

 

IN WITNESS WHEREOF, the parties hereto have caused
this Agreement to be duly executed as of the date first written above.

 

	 	INTERNATIONAL BUSINESS MACHINES CORPORATION
	 	 
	 	By:	/s/ Frank Sedlarcik
	 	 	Name: Frank Sedlarcik
	 	 	Title:  Vice president, Assistant General Counsel and Secretary
	 	 
	 	KYNDRYL HOLDINGS, INC.
	 	 
	 	By:	/s/ Simon Beaumont
	 	 	Name: Simon Beaumont
	 	 	Title: President

 

[Signature
Page to Stockholder and Registration Rights Agreement]Exhibit 10.9

 

Kyndryl 2021 Long-Term Performance Plan

 

1. Objectives.

 

The Kyndryl 2021 Long-Term Performance Plan (the “Plan”)
is designed to attract, motivate and retain selected employees of, and other individuals providing services to, the Company. These objectives
are accomplished by making long-term incentive and other awards under the Plan, thereby providing Participants with a proprietary interest
in the growth and performance of the Company.

 

2. Definitions.

 

(a) “Assumed Award” – An award granted to certain
employees, officers, and directors of the Company and its subsidiaries under a Prior Plan, which award is assumed by the Company and converted
into an Award in connection with the Spin-Off, pursuant to the terms of the Employee Matters Agreement.

 

(b) “Awards” – The grant of any form of stock
option, stock appreciation right, stock or cash award, whether granted singly, in combination or in tandem, to a Participant pursuant
to such terms, conditions, performance requirements, limitations and restrictions as the Committee may establish in order to fulfill the
objectives of the Plan.

 

(c) “Award Agreement” – An agreement between
the Company and a Participant that sets forth the terms, conditions, performance requirements, limitations and restrictions applicable
to an Award.

 

(d) “Beneficial Ownership” – Beneficial ownership
within the meaning of Rule 13d-3 promulgated under Section 13 of the Exchange Act.

 

(e) “Board” – The Board of Directors of Kyndryl.

 

(f) “Cause”
 – As reasonably determined by Kyndryl, the occurrence of any of the following: (i) embezzlement, misappropriation of corporate
funds or other material acts of dishonesty; (ii) commission or conviction of any felony or of any misdemeanor involving moral turpitude,
or entry of a plea of guilty or nolo contendere to any felony or misdemeanor (other than a minor traffic violation or other minor
infraction); (iii) engagement in any activity that the employee knows or should know could harm the business or reputation of the
Company; (iv) failure to adhere to the Company’s corporate codes, policies or procedures; (v) a breach of any covenant
in any employment agreement or any intellectual property agreement, or a breach of any other provision of the employment agreement, in
either case if the breach is not cured to the Company’s satisfaction within a reasonable period after notice of the breach (no notice
and cure period is required if the breach cannot be cured); (vi) failure to perform duties or follow management direction, which
failure is not cured to the Company’s satisfaction within a reasonable period of time after a written demand for substantial performance
is delivered to (no notice or cure period is required if the failure to perform cannot be cured); (vii) violation of any statutory,
contractual or common law duty or obligation to the Company, including, without limitation, the duty of loyalty; (viii) rendering
of services for any organization or engaging directly or indirectly in any business which is or becomes competitive with the Company,
or which organization or business, or the rendering of services to such organization or business, is or becomes otherwise prejudicial
to or in conflict with the interests of the Company; or (ix) acceptance of an offer to engage in or associate with any business which
is or becomes competitive with the Company; provided, however, that the mere failure to achieve performance objectives shall
not constitute Cause.

 

(g) “Change in Control”
 – Unless the applicable Award Agreement or the Committee provides otherwise, the first to occur of any of the following events:

 

		(i)	the acquisition by any Person or related “group” (as such term is used in Section 13(d) and Section 14(d) of
the Exchange Act) of Persons, or Persons acting jointly or in concert, of Beneficial Ownership (including control or direction) of more
than 50% (on a fully diluted basis) of either (A) the then-outstanding shares of Common Stock, including shares of Common Stock issuable
upon the exercise of options or warrants, the conversion of convertible stock or debt, and the exercise of any similar right to acquire
such shares of Common Stock or (B) the combined voting power of the then-outstanding voting securities of the Company entitled to
vote in the election of Directors (the “Outstanding Company Voting Securities”), but excluding any acquisition by the Company
or any of its affiliates, its Permitted Transferees or any of their respective affiliates or by any employee benefit plan sponsored or
maintained by the Company;

 

    

     

    

 

		(ii)	a change in the composition of the Board such that members of the Board during any consecutive 24-month period (the “Incumbent
Directors”) cease to constitute a majority of the Board. Any person becoming a Director through election or nomination for election
approved by a valid vote of at least a majority of the Incumbent Directors shall be deemed an Incumbent Director; provided, however,
that no individual becoming a Director as a result of an actual or threatened election contest, as such terms are used in Rule 14a-12
of Regulation 14A promulgated under the Exchange Act, or as a result of any other actual or threatened solicitation of proxies or consents
by or on behalf of any person other than the Board, shall be deemed an Incumbent Director;

 

		(iii)	the approval by the stockholders of the Company of a plan of complete dissolution or liquidation of the Company; or

 

		(iv)	the consummation of a reorganization, recapitalization, merger, amalgamation, consolidation, statutory share exchange or similar form
of corporate transaction involving (x) the Company or (y) any of its subsidiaries, but in the case of this clause (y) only
if Outstanding Company Voting Securities are issued or issuable (a “Business Combination”), or sale, transfer or other disposition
of all or substantially all of the business or assets of the Company to an entity that is not an affiliate of the Company (a “Sale”),
unless immediately following such Business Combination or Sale: (A) more than 50% of the total voting power of the entity resulting
from such Business Combination or the entity that acquired all or substantially all of the business or assets of the Company in such Sale
(in either case, the “Surviving Company”), or the ultimate parent entity that has Beneficial Ownership of sufficient voting
power to elect a majority of the board of directors (or analogous governing body) of the Surviving Company (the “Parent Company”),
is represented by the Outstanding Company Voting Securities that were outstanding immediately prior to such Business Combination or Sale
(or, if applicable, is represented by shares of Common Stock into which the Outstanding Company Voting Securities were converted pursuant
to such Business Combination or Sale), and such voting power among the holders thereof is in substantially the same proportion as the
voting power of the Outstanding Company Voting Securities among the holders thereof immediately prior to the Business Combination or Sale,
(B) no Person (other than any employee benefit plan sponsored or maintained by the Surviving Company or the Parent Company) is or
becomes the beneficial owner, directly or indirectly, of more than 50% of the total voting power of the outstanding voting securities
eligible to elect members of the board of directors (or the analogous governing body) of the Parent Company (or, if there is no Parent
Company, the Surviving Company) and (C) at least a majority of the members of the board of directors (or the analogous governing
body) of the Parent Company (or, if there is no Parent Company, the Surviving Company) following the consummation of the Business Combination
or Sale were Board members at the time of the Board’s approval of the execution of the initial agreement providing for such Business
Combination or Sale.

 

(h) “Common Stock” or “stock” –
Authorized and issued or unissued Common Stock of Kyndryl, at such par value as may be established from time to time.

 

(i) “Code” – The Internal Revenue Code of 1986,
as amended from time to time.

 

(j) “Committee” – The committee designated by
the Board to administer the Plan.

 

(k) “Company” – Kyndryl and its affiliates and
subsidiaries including subsidiaries of subsidiaries and partnerships and other business ventures in which Kyndryl has an equity interest.

 

    2

     

    

 

(l) “Director” – Any member of the Board.

 

(m) “Exchange Act” – The U.S. Securities Exchange
Act of 1934, as amended, and any successor thereto. References to any section of (or rule promulgated under) the Exchange Act shall
be deemed to include any rules, regulations or other interpretative guidance under such section or rule, and any amendments or successors
thereto.

 

(n) “Fair Market Value” – The average of the
high and low prices of Common Stock on the New York Stock Exchange for the date in question, provided that, if no sales of Common Stock
were made on said exchange on that date, the average of the high and low prices of Common Stock as reported for the most recent preceding
day on which sales of Common Stock were made on said exchange.

 

(o) “Kyndryl” – Kyndryl Holdings, Inc.

 

(p) “Participant” – An individual to whom an
Award has been made under the Plan. Awards may be made to (i) any employee of, or any other individual providing services to, the
Company, or (ii) any prospective employee or other service provider of the Company who has accepted an offer of employment or service
from the Company. However, incentive stock options may be granted only to individuals who are employed by Kyndryl or by a subsidiary corporation
(within the meaning of section 424(f) of the Code) of Kyndryl, including a subsidiary that becomes such after the adoption of the
Plan.

 

(q)  “Performance Period” – A multi-year period
of no more than five consecutive calendar years over which one or more of the performance criteria listed in Section 6 shall be measured
pursuant to the grant of Long-Term Performance Incentive Awards (whether such Awards take the form of stock, stock units or equivalents
or cash). Performance Periods may overlap one another, but no two Performance Periods may consist solely of the same calendar years.

 

(r) “Permitted Transferee” – A Person to whom
an Award may be transferred in accordance with Section 10.

 

(s) “Person” – A “person” as defined
in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof, except that
such term shall not include (i) the Company, (ii) a trustee or other fiduciary holding securities under an employee benefit
plan of the Company, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities or (iv) a
corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership
of shares of Common Stock of the Company.

 

(t) “Prior Plans” – Any Long-Term Performance
Plan of International Business Machines Corporation.

 

(u) “Spin-Off” – The distribution of shares
of Common Stock to the stockholders of International Business Machines Corporation in 2021 pursuant to the Separation and Distribution
Agreement and the Employee Matters Agreement between the Company and International Business Machines Corporation entered into in connection
with such distribution.

 

(v) “Substitute Awards” – An Award granted under
the Plan upon the assumption of, or in substitution for, outstanding equity awards previously granted by a company or other entity in
connection with a corporate transaction, such as a merger, combination, consolidation or acquisition of property or stock; provided,
however, that in no event shall the term “Substitute Award” be construed to refer to an award made in connection with
the cancellation and repricing of an option or stock appreciation right.

 

3. Common Stock Available for Awards.

 

The number of shares of Common Stock that may be issued under the Plan
for Awards granted wholly or partly in stock during the term of the Plan is 22,400,000, which includes the number of shares of Common Stock subject
to the Assumed Awards. Shares of Common Stock may be made available from the authorized but unissued shares of the Company or from shares
held in the Company’s treasury and not reserved for some other purpose. For purposes of determining the number of shares of Common
Stock issued under the Plan, no shares shall be deemed issued until they are actually delivered to a Participant, or such other person
in accordance with Section 10. Shares covered by Awards that either wholly or in part are not earned, or that expire or are forfeited,
terminated, canceled, settled in cash, payable solely in cash or exchanged for other awards, shall be available for future issuance under
Awards. However, shares of Common Stock tendered to or withheld by the Company in connection with the exercise of stock options or SARs,
or the payment of tax withholding on any Award, shall not be available for future issuance under Awards. The maximum amount (based on
the fair value of shares of Common Stock underlying Awards on the grant date as determined in accordance with applicable financial accounting
rules) of Awards that may be granted in any single fiscal year to any non-employee member of the Board, taken together with any cash fees
paid to such non-employee member of the Board during such fiscal year, shall be $750,000.

 

    3

     

    

 

Substitute Awards shall not reduce the shares of Common Stock authorized
for grant under the Plan. Additionally, in the event that a company acquired by the Company or any affiliate or with which the Company
or any affiliate combines has shares available under a pre-existing plan approved by stockholders and not approved in contemplation of
such acquisition or combination, the shares available for grant pursuant to the terms of such pre-existing plan (as adjusted, to the extent
appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination to determine
the consideration payable to the holders of common stock of the entities party to such acquisition or combination) may be used for Awards
under the Plan and shall not reduce the shares of Common Stock authorized for grant under the Plan; provided that Awards using
such available shares shall not be made after the date awards or grants could have been made under the terms of the pre-existing plan,
absent the acquisition or combination, and shall only be made to individuals who were not employed by or providing services to the Company
immediately prior to such acquisition or combination.

 

4. Administration.

 

The Plan shall be administered by the Committee, which shall have full
power to select Participants, to interpret the Plan, to grant waivers of Award restrictions, to continue, accelerate or suspend exercisability,
vesting or payment of an Award and to adopt such rules, regulations and guidelines for carrying out the Plan as it may deem necessary
or proper. These powers include, but are not limited to, the adoption of modifications, amendments, procedures, subplans and the like
as necessary to comply with provisions of the laws and regulations of the countries in which the Company operates in order to assure the
viability of Awards granted under the Plan and to enable Participants regardless of where employed to receive advantages and benefits
under the Plan and such laws and regulations.

 

5. Delegation of Authority.

 

The Committee may delegate to officers of the Company its duties, power
and authority under the Plan pursuant to such conditions or limitations as the Committee may establish, except that only the Committee
or the Board may select, and grant Awards to, Participants who are subject to Section 16 of the Securities Exchange Act of 1934.

 

6. Awards.

 

The Committee shall determine the type or types of Award(s) to
be made to each Participant and shall set forth in the related Award Agreement the terms, conditions, performance requirements, and limitations
applicable to each Award. Awards may include but are not limited to those listed in this Section 6. Notwithstanding anything to the
contrary herein, and subject to Section 15, Awards shall be subject to a condition that vesting of (or lapsing of restrictions on)
such Award will not occur until at least the first anniversary of the date of grant; provided, however, that the Committee
may, in its sole discretion, (i) accelerate the vesting of Awards or otherwise lapse or waive such minimum vesting condition in connection
with (A) the Participant’s termination of employment (including as a result of death, disability or retirement) or (B) a
Change in Control (subject to the requirements of Section 15) and (ii) grant Awards that are not subject to the minimum vesting
condition with respect to (A) 5% or less of the total shares of Common Stock available for Awards (as set forth in Section 3,
as may be adjusted pursuant to Section 14), (B) Awards made to non-employee members of the Board that
occur in connection with the Company’s annual meeting of stockholders, and which vest on the earlier of the one-year anniversary
of the date of grant or the date of the Company’s next annual meeting of stockholders which is at least 50 weeks after the immediately
preceding year’s annual meeting and (C) Substitute Awards that were scheduled to vest within the one year minimum vesting
period. Awards may be granted singly, in combination or in tandem. Awards may also be made in combination or in tandem with, in replacement
or payment of, or as alternatives to, grants, rights or compensation earned under any other plan of the Company, including the plan of
any acquired entity.

 

    4

     

    

 

(a)  Stock
Option – A grant of a right to purchase a specified number of shares of Common Stock the exercise price of which shall be not less
than 100% of Fair Market Value on the date of grant of such right, as determined by the Committee, provided that, in the case of a stock
option granted retroactively in tandem with or as substitution for another award granted under any plan of the Company, the exercise price
may be the same as the purchase or designated price of such other award. A stock option may be in the form of an incentive stock option
(“ISO”) which, in addition to being subject to applicable terms, conditions and limitations established by the Committee,
complies with section 422 of the Code. The number of shares of Common Stock that shall be available for issuance under ISOs granted under
the Plan is limited to 22,400,000.

 

(b)  Stock
Appreciation Right – A right to receive a payment, in cash and/or Common Stock, equal in value to the excess of the Fair Market
Value of a specified number of shares of Common Stock on the date the stock appreciation right (SAR) is exercised over the grant price
of the SAR, which shall not be less than 100% of the Fair Market Value on the date of grant of such SAR, as determined by the Committee,
provided that, in the case of a SAR granted retroactively in tandem with or as substitution for another award granted under any plan of
the Company, the grant price may be the same as the exercise or designated price of such other award

 

(c)  Stock
Award – An Award made in stock and denominated in units of stock. All or part of any stock award may be subject to conditions established
by the Committee, and set forth in the Award Agreement, which may include, but are not limited to, continuous service with Company, achievement
of specific business objectives, increases in specified indices, attaining growth rates, and other comparable measurements of Company
performance. An Award made in stock or denominated in units of stock that is subject to restrictions on transfer and/or forfeiture provisions
may be referred to as an Award of “Restricted Stock” or “Restricted Stock Units”.

 

(d)  Cash
Award – An Award denominated in cash with the eventual payment amount subject to future service and such other restrictions and
conditions as may be established by the Committee, and as set forth in the Award Agreement, including, but not limited to, continuous
service with the Company, achievement of specific business objectives, increases in specified indices, attaining growth rates, and other
comparable measurements of Company performance.

 

7. Payment of Awards.

 

Payment of Awards may be made in the form of cash, stock or
combinations thereof and may include such restrictions as the Committee shall determine. Further, with Committee approval, payments
may be deferred, either in the form of installments or as a future lump-sum payment, in accordance with such procedures as may be
established from time to time by the Committee. Any deferred payment, whether elected by the Participant or specified by the Award
Agreement or the Committee, may require the payment to be forfeited in accordance with the provisions of Section 13. Dividends
or dividend equivalent rights may be extended to and made part of any Award denominated in stock or units of stock (for the
avoidance of doubt, excluding stock options or SARs), subject to such terms, conditions and restrictions as the Committee may
establish; provided, that, notwithstanding anything herein to the contrary, any dividends or dividend equivalents
payable with respect to any Award or any portion of an Award may only be paid to the Participant to the extent the vesting
conditions applicable to such Award or portion thereof are subsequently satisfied and the Award or portion thereof to which such
dividend or dividend equivalent relates, and any dividends or dividend equivalents with respect to any Award or any portion thereof
does not become vested shall be forfeited. The Committee may also establish rules and procedures for the crediting of interest
on deferred cash payments and dividend equivalents for deferred payments denominated in stock or units of stock. At the discretion
of the Committee, a Participant may be offered an election to substitute an Award for another Award or Awards of the same or
different type.

 

    5

     

    

 

8. Stock Option Exercise.

 

The price at which shares of Common Stock may be purchased under a
stock option shall be paid in full in cash at the time of the exercise or, if permitted by the Committee, by means of tendering Common
Stock or surrendering another Award or any combination thereof. The Committee shall determine acceptable methods of tendering Common Stock
or other Awards and may impose such conditions on the use of Common Stock or other Awards to exercise a stock option as it deems appropriate.

 

9. Tax Withholding.

 

Prior to the payment or settlement of any Award, the Participant must
pay, or make arrangements acceptable to the Company for the payment of, any and all federal, state and local tax withholding that in the
opinion of the Company is required by law. The Company shall have the right to deduct applicable taxes from any Award payment and withhold,
at the time of delivery or vesting of shares under the Plan and up to the maximum permissible withholding amounts, an appropriate number
of shares for payment of taxes required by law or to take such other action as may be necessary in the opinion of the Company to satisfy
all obligations for withholding of such taxes.

 

10. Transferability.

 

No Award shall be transferable or assignable, or payable to or exercisable
by, anyone other than the Participant to whom it was granted, except (i) by law, will or the laws of descent and distribution, (ii) as
a result of the disability of a Participant or (iii) that the Committee (in the form of an Award Agreement or otherwise) may permit
transfers of Awards by gift or otherwise to a member of a Participant’s immediate family and/or trusts whose beneficiaries are members
of the Participant’s immediate family, or to such other persons or entities as may be approved by the Committee. Notwithstanding
the foregoing, in no event shall ISOs be transferable or assignable other than by will or by the laws of descent and distribution.

 

11. Amendment, Modification, Suspension
or Discontinuance of the Plan.

 

The Board may amend, modify, suspend or terminate the Plan for the
purpose of meeting or addressing any changes in legal requirements or for any other purpose permitted by law. Subject to changes in law
or other legal requirements that would permit otherwise, the Plan may not be amended without the consent of the holders of a majority
of the shares of Common Stock then outstanding, to (i) increase the aggregate number of shares of Common Stock that may be issued
under the Plan (except for adjustments pursuant to Section 14 of the Plan), (ii) permit the granting of stock options or SARs
with exercise or grant prices lower than those specified in Section 6, (iii) reduce the exercise or grant price of any stock
option or SAR, (iv) cancel any outstanding stock option or SAR and replace it with a new stock option or SAR (with a lower exercise
or grant price, as the case may be) or other Award or cash in a manner which would either (A) be reportable on the Company’s
proxy statement as stock options that have been “repriced” (as such term is used in Item 402 of Regulation S-K promulgated
under the Exchange Act), or (B) result in any “repricing” for financial statement reporting purposes (or otherwise cause
the Award to fail to qualify for equity accounting treatment) and (v) take any other action which is considered a “repricing”
for purposes of the stockholder approval rules of the applicable securities exchange or inter-dealer quotation service on which the
Common Stock is listed or quoted.

 

12. Termination of Employment.

 

If the employment of a Participant terminates, other than as a result
of the death or disability of a Participant, all unexercised, deferred and unpaid Awards shall be canceled immediately, unless the Award
Agreement provides otherwise. In the event of the death of a Participant or in the event a Participant is deemed by the Company to be
disabled and eligible for benefits under the terms of the Kyndryl Long Term Disability Plan (or any successor plan or similar plan of
another employer), the Participant’s estate, beneficiaries or representative, as the case may be, shall have the rights and duties
of the Participant under the applicable Award Agreement.

 

    6

     

    

 

13. Cancellation and Rescission of
Awards/Clawback.

 

(a)  Unless
the Award Agreement specifies otherwise, the Committee may cancel, rescind, suspend, withhold or otherwise limit or restrict any unexpired,
unpaid, or deferred Awards at any time if the Participant is not in compliance with all applicable provisions of the Award Agreement and
the Plan, or if the Participant engages in any “Detrimental Activity.” For purposes of this Section 13, “Detrimental
Activity” shall include: (i) the rendering of services, including the acceptance of an offer to render services, for any organization
or engaging directly or indirectly in any business which is or becomes competitive with the Company, or which organization or business,
or the rendering of services to such organization or business, is or becomes otherwise prejudicial to or in conflict with the interests
of the Company; (ii) the disclosure to anyone outside the Company, or the use in other than the Company’s business, without
prior written authorization from the Company, of any confidential information or material, as defined in the Company’s Agreement
Regarding Confidential Information and Intellectual Property, relating to the business of the Company, acquired by the Participant either
during or after employment with the Company; (iii) the failure or refusal to disclose promptly and to assign to the Company, pursuant
to the Company’s Agreement Regarding Confidential Information and Intellectual Property, all right, title and interest in any invention
or idea, patentable or not, made or conceived by the Participant during employment by the Company, relating in any manner to the actual
or anticipated business, research or development work of the Company or the failure or refusal to do anything reasonably necessary to
enable the Company to secure a patent where appropriate in the United States and in other countries; (iv) activity that results in
termination of the Participant’s employment for Cause; (v) a violation of any rules, policies, procedures or guidelines of
the Company, including but not limited to the Company’s Business Conduct Guidelines; (vi) any attempt directly or indirectly
to induce any employee of the Company to be employed or perform services elsewhere or any attempt directly or indirectly to solicit the
trade or business of any current or prospective customer, supplier or partner of the Company; or (vii) the Participant being convicted
of, or entering a guilty plea with respect to, a crime, whether or not connected with the Company.

 

(b)  Upon
exercise, payment or delivery pursuant to an Award, the Participant shall certify in a manner acceptable to the Company that he or she
is in compliance with the terms and conditions of the Plan. In the event a Participant fails to comply with the provisions of paragraphs
(a)(i)-(vii) of this Section 13 prior to, or during the Rescission Period, then any exercise, payment or delivery may be rescinded
within two years after such exercise, payment or delivery. In the event of any such rescission, the Participant shall pay to the Company
the amount of any gain realized or payment received as a result of the rescinded exercise, payment or delivery, in such manner and on
such terms and conditions as may be required, and the Company shall be entitled to set-off against the amount of any such gain any amount
owed to the Participant by the Company. As used herein, Rescission Period shall mean that period of time established by the Committee
which shall not be less than 6 months after any exercise, payment or delivery pursuant to an Award.

 

 (c)  The Committee shall have full authority to implement any policies and procedures necessary to comply with Section 10D of the Exchange Act and any rules promulgated thereunder and any other regulatory regimes. Further, to the extent required by applicable law (including, without limitation, Section 304 of the Sarbanes-Oxley Act and Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act) and/or the rules and regulations of the securities exchange or inter-dealer quotation service on which the shares of Common Stock are listed or quoted, or if so required pursuant to a written policy adopted by the Company, Awards shall be subject (including on a retroactive basis) to clawback, forfeiture or similar requirements (and such requirements shall be deemed incorporated by reference into all outstanding Award Agreements).

 

14. Adjustments.

 

In the event of any change in the outstanding Common Stock of the Company
by reason of a stock split, stock dividend, combination or reclassification of shares, recapitalization, merger, or similar event, the
Committee may adjust proportionately: (a) the number of shares of Common Stock (i) available for issuance under the Plan, (ii) available
for issuance under ISOs, (iii) for which Awards may be granted to an individual Participant set forth in Section 6, and (iv) covered
by outstanding Awards denominated in stock or units of stock; (b) the exercise and grant prices related to outstanding Awards; and
(c) the appropriate Fair Market Value and other price determinations for such Awards. Notwithstanding the foregoing, in the event
of any change in the outstanding Common Stock of the Company by reason of a stock split or a reverse stock split, the above-referenced
proportionate adjustments, if applicable, shall be mandatory.

 

    7

     

    

 

In the event of any other change affecting the Common Stock or any
distribution (other than normal cash dividends) to holders of Common Stock, such adjustments in the number and kind of shares and the
exercise, grant and conversion prices of the affected Awards as may be deemed equitable by the Committee, including adjustments to avoid
fractional shares, shall be made to give proper effect to such event. In the event of a corporate merger, consolidation, acquisition of
property or stock, separation, reorganization or liquidation, the Committee shall be authorized to cause Kyndryl to issue or assume stock
options, whether or not in a transaction to which section 424(a) of the Code applies, by means of substitution of new stock options
for previously issued stock options or an assumption of previously issued stock options. In such event, the aggregate number of shares
of Common Stock available for issuance under Awards under Section 3, including the individual Participant maximums set forth in Section 6
will be increased to reflect such substitution or assumption.

 

15. Effect of a Change in Control
on Awards.

 

Except to the extent otherwise provided in an Award Agreement, or any
applicable employment, consulting, change-in-control, severance or other agreement between the Participant and the Company, in the event
of a Change in Control, notwithstanding any provision of the Plan to the contrary:

 

(a)  If
the acquirer or successor company in such Change in Control has agreed to provide for the substitution, assumption, exchange or other
continuation of Awards granted pursuant to the Plan, then, if the Participant’s employment with or service to the Company or an
Affiliate is terminated by the Company without Cause (and other than due to death or Disability) on or within 24 months following a Change
in Control, then unless otherwise provided by the Committee, all stock options and SARs held by such Participant shall become immediately
exercisable with respect to 100% of the shares of Common Stock subject to such stock options and SARs, and that the restricted period
(and any other conditions) shall expire immediately with respect to 100% of the shares of Restricted Stock and Restricted Stock Units
and any other Awards held by such Participant (including a waiver of any applicable performance conditions); provided that if the
vesting or exercisability of any Award would otherwise be subject to the achievement of performance conditions, the portion of such Award
that shall become fully vested and immediately exercisable shall be based on the assumed achievement of actual or target performance as
determined by the Committee.

 

(b)  If
the acquirer or successor company in such Change in Control has not agreed to provide for the substitution, assumption, exchange or other
continuation of Awards granted pursuant to the Plan, then unless otherwise provided by the Committee, all Options and SARs held by such
Participant shall become immediately exercisable with respect to 100% of the shares of Common Stock subject to such Options and SARs,
and the Restricted Period (and any other conditions) shall expire immediately with respect to 100% of the shares of Restricted Stock and
Restricted Stock Units and any other Awards held by such Participant (including a waiver of any applicable performance conditions); provided
that if the vesting or exercisability of any Award would otherwise be subject to the achievement of performance conditions, the portion
of such Award that shall become fully vested and immediately exercisable shall be based on the assumed achievement of actual or target
performance as determined by the Committee.

 

(c)  In
addition, the Committee may upon at least 10 days’ advance notice to the affected Participants, cancel any outstanding Award and
pay to the holders thereof, in cash, securities or other property (including of the acquiring or successor company), or any combination
thereof, the value of such Awards based upon the price per share of Common Stock received or to be received by other stockholders of the
Company in the event (it being understood that any Option or SAR having a per-share exercise or hurdle price equal to, or in excess of,
the Fair Market Value (as of the date specified by the Committee) of a share of Common Stock subject thereto may be canceled and terminated
without any payment or consideration therefor). Notwithstanding the above, the Committee shall exercise such discretion over the timing
of settlement of any Award subject to Code Section 409A at the time such Award is granted.

 

(d)  To
the extent practicable, the provisions of this Section 15 shall occur in a manner and at a time that allows affected Participants
the ability to participate in the Change in Control transaction with respect to the shares of Common Stock subject to their Awards.

 

    8

     

    

 

16. Section 409A of the Code.

 

 (a)  It is intended that the Plan comply with Section 409A of the Code, and all provisions of the Plan shall be construed and interpreted in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A of the Code. Each Participant is solely responsible and liable for the satisfaction of all taxes and penalties that may be imposed on or in respect of such Participant in connection with the Plan or any other plan maintained by the Company, including any taxes and penalties under Section 409A of the Code, and the Company shall not have any obligation to indemnify or otherwise hold such Participant or any beneficiary harmless from any or all of such taxes or penalties. With respect to any Award that is considered “deferred compensation” subject to Section 409A of the Code, references in the Plan to “termination of employment” (and substantially similar phrases) shall mean “separation from service” within the meaning of Section 409A of the Code. For purposes of Section 409A of the Code, each of the payments that may be made in respect of any Award granted under the Plan is designated as a separate payment.

 

 (b)  Notwithstanding anything in the Plan to the contrary, if the Participant is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, no payments or deliveries in respect of any Awards that are “deferred compensation” subject to Section 409A of the Code shall be made to such Participant prior to the date that is six months after the date of such Participant’s “separation from service” within the meaning of Section 409A of the Code or, if earlier, the Participant’s date of death. All such delayed payments or deliveries will be paid or delivered (without interest) in a single lump sum on the earliest date permitted under Section 409A of the Code that is also a business day.

 

 (c)  In the event that the timing of payments in respect of any Award that would otherwise be considered “deferred compensation” subject to Section 409A of the Code would be accelerated upon the occurrence of (A) a Change in Control, no such acceleration shall be permitted unless the event giving rise to the Change in Control satisfies the definition of a change in the ownership or effective control of a corporation, or a change in the ownership of a substantial portion of the assets of a corporation pursuant to Section 409A of the Code and any Treasury Regulations promulgated thereunder, or (B) a Disability, no such acceleration shall be permitted unless the Disability also satisfies the definition of “disability” pursuant to Section 409A of the Code and any Treasury Regulations promulgated thereunder.

 

17. Miscellaneous.

 

(a)  Any
notice to the Company required by any of the provisions of the Plan shall be addressed to the chief human resources officer of Kyndryl
in writing, and shall become effective when it is received.

 

(b)  The
Plan shall be unfunded and the Company shall not be required to establish any special account or fund or to otherwise segregate or encumber
assets to ensure payment of any Award.

 

(c)  Nothing
contained in the Plan shall prevent the Company from adopting other or additional compensation arrangements or plans, subject to stockholder
approval if such approval is required, and such arrangements or plans may be either generally applicable or applicable only in specific
cases.

 

(d)  No
Participant shall have any claim or right to be granted an Award under the Plan and nothing contained in the Plan shall be deemed or be
construed to give any Participant the right to be retained in the employ of the Company or to interfere with the right of the Company
to discharge any Participant at any time without regard to the effect such discharge may have upon the Participant under the Plan. Except
to the extent otherwise provided in any plan or in an Award Agreement, no Award under the Plan shall be deemed compensation for purposes
of computing benefits or contributions under any other plan of the Company.

 

(e)  The
Plan and each Award Agreement shall be governed by the laws of the State of Delaware, excluding any conflicts or choice of law rule or
principle that might otherwise refer construction or interpretation of the Plan to the substantive law of another jurisdiction. Unless
otherwise provided in the Award Agreement, recipients of an Award under the Plan are deemed to submit to the exclusive jurisdiction and
venue of the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware lacks jurisdiction over
such action or proceeding, then another court of the State of Delaware or, if no court of the State of Delaware has jurisdiction, then
the United States District Court for the District of Delaware), to resolve any and all issues that may arise out of or relate to the Plan
or any related Award Agreement.

 

    9

     

    

 

(f)  In
the event that a Participant or the Company brings an action to enforce the terms of the Plan or any Award Agreement and the Company prevails,
the Participant shall pay all costs and expenses incurred by the Company in connection with that action, including reasonable attorneys’
fees, and all further costs and fees, including reasonable attorneys’ fees incurred by the Company in connection with collection.

 

(g)  The
Committee and any officers to whom it may delegate authority under Section 5 shall have full power and authority to interpret the
Plan and to make any determinations thereunder, including determinations under Section 13, and the Committee’s or such officer’s
determinations shall be binding and conclusive. Determinations made by the Committee or any such officer under the Plan need not be uniform
and may be made selectively among individuals, whether or not such individuals are similarly situated.

 

(h)  If
any provision of the Plan is or becomes or is deemed invalid, illegal or unenforceable in any jurisdiction, or would disqualify the Plan
or any Award under any law deemed applicable by the Committee, such provision shall be construed or deemed amended or limited in scope
to conform to applicable laws or, in the discretion of the Committee, it shall be stricken and the remainder of the Plan shall remain
in full force and effect.

 

(i)  The
Plan shall become effective on the date it is approved by the requisite vote of the stockholder of the Company.

 

(j)  Notwithstanding
anything in this Plan to the contrary, each Assumed Award shall be subject to the terms and conditions of the Prior Plan and award agreement
to which such Assumed Award was subject immediately prior to the Spin-Off, subject to the adjustment of such Assumed Award by the Executive
Compensation and Management Resources Committee of International Business Machines Corporation and the terms of the Employee Matters Agreement;
provided that following the date of the Spin-Off, each such Assumed Award shall relate solely to shares of Common Stock and be administered
by the Committee in accordance with the administrative procedures in effect under this Plan.

 

Federal Income Tax Consequences

 

The Company has been advised by counsel that, in general, under the
Internal Revenue Code, as presently in effect, a Participant will not be deemed to recognize any income for federal income tax purposes
at the time an option or SAR is granted or a restricted stock award is made, nor will the Company be entitled to a tax deduction at that
time. However, when any part of an option or SAR is exercised, when restrictions on restricted stock lapse, or when an unrestricted stock
award is made, the federal income tax consequences may be summarized as follows:

 

1.  In
the case of an exercise of a stock option other than an ISO, the optionee will generally recognize ordinary income in an amount equal
to the excess of the fair market value of the shares on the exercise date over the option price.

 

2.  In
the case of an exercise of a SAR, the Participant will generally recognize ordinary income on the exercise date in an amount equal to
any cash and the fair market value of any unrestricted shares received.

 

3.  In
the case of an exercise of an option or SAR payable in restricted stock, or in the case of an award of restricted stock, the immediate
federal income tax effect for the recipient will depend on the nature of the restrictions. Generally, the fair market value of the stock
will not be taxable to the recipient as ordinary income until the year in which his or her interest in the stock is freely transferable
or is no longer subject to a substantial risk of forfeiture. However, the recipient may elect to recognize income when the stock is received,
rather than when his or her interest in the stock is freely transferable or is no longer subject to a substantial risk of forfeiture.
If the recipient makes this election, the amount taxed to the recipient as ordinary income is determined as of the date of receipt of
the restricted stock.

 

    10

     

    

 

4.  In
the case of ISOs, there is generally no tax liability at time of exercise. However, the excess of the fair market value of the stock on
the exercise date over the option price is included in the optionee’s income for purposes of the alternative minimum tax. If no
disposition of the ISO stock is made before the later of one year from the date of exercise and two years from the date of grant, the
optionee will realize a capital gain or loss upon a sale of the stock, equal to the difference between the option price and the sale price.
If the stock is not held for the required period, ordinary income tax treatment will generally apply to the excess of the fair market
value of the stock on the date of exercise (or, if less, the amount of gain realized on the disposition of the stock) over the option
price, and the balance of any gain or any loss will be treated as capital gain or loss. In order for ISOs to be treated as described above,
the Participant must remain employed by the Company (or a subsidiary in which the Company holds at least 50 percent of the voting power)
from the ISO grant date until three months before the ISO is exercised. The three-month period is extended to one year if the Participant’s
employment terminates on account of disability. If the Participant does not meet the employment requirement, the option will be treated
for federal income tax purposes as an option as described in paragraph 5 below. A Participant who exercises an ISO might also be subject
to an alternative minimum tax.

 

5.  Upon
the exercise of a stock option other than an ISO, the exercise of a SAR, the award of stock, or the recognition of income on restricted
stock, the Company will generally be allowed an income tax deduction equal to the ordinary income recognized by a Participant. The Company
will not receive an income tax deduction as a result of the exercise of an ISO, provided that the ISO stock is held for the required period
as described above. When a cash payment is made pursuant to the Award, the recipient will recognize the amount of the cash payment as
ordinary income, and the Company will generally be entitled to a deduction in the same amount.

 

    11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]